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THE EFFICACY AND SAFETY OF INTRAVENOUS SEDATION IN 
CHILDREN UNDER THE AGE OF 10 YEARS 
  
This study was done to show that sedation is a safe and a viable option in young children.  
Dental procedures were done on children aged two to ten years.  Two hundred children 
were included in the study.  In all of these children the procedures were completed.  Only 
two children were excluded, because an intravenous line could not be placed on the one 
child, and the other child was unmanageable under sedation.   
The safety of sedation was evaluated looking at the incidence of adverse events and 
complications.  
 No serious adverse effects or complications occurred.   
The complications that occurred were all corrected with minimal or non-invasive 
interventions.  Only six of the two hundred children required oxygen to correct a drop in 
oxygen saturation.   
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CHAPTER ONE 
 
INTRODUCTION   
 
In the British Dental Journal of the 10th of May 2003 an article was published with the 
topic: “Intravenous conscious sedation in patients under 16 years of age.  Fact or fiction?” 
(Robb, Hosey & Leitch 2003).  They found in the study of 18 patients between 11 and 15 
years of age, that the patients could be managed successfully with conscious sedation.  
They suggested that further studies in this population group be carried out. This was indeed 
a very encouraging statement coming from clinicians who were sceptical that conscious 
sedation is not possible in children.   
 
The aim of this research study was to prove that intravenous sedation in children, with 
different drugs, done by an experienced and trained sedation practitioner, can be done 
safely and effectively in children outside the operating room.   
  
From 1985 – 1992, before The American Academy of Paediatrics (AAP) revised the 
guidelines for paediatric sedation, the guidelines only referred to sedation as being light, 
conscious sedation, or deep sedation (Cravero & Blike 2004).  In recent years new 
definitions and guidelines have been developed.  Revised guidelines from both the AAP 
and the American Society of Anesthesiologists (ASA) have eliminated and largely replaced 
the term conscious sedation with the term moderate sedation and analgesia (Cravero & 
Blike 2004:1355-1356). This is probably a more descriptive term of what sedation really is.   
 
The term procedural sedation is also used today.  This term describes a depressed level of 
consciousness and is used by some as a substitute for the term conscious sedation. This 
creates a wrong impression as conscious sedation is only one level of the different levels of 
procedural sedation and analgesia.  Kraus and Green (2000:938) stated that procedural 
sedation should be viewed as a continuum of sedation levels ranging from light or minimal 
sedation to deep sedation.  The depth of sedation can easily be titrated by selective 
administration of sedatives and analgesics.  The term procedural sedation is used by some 
physicians to practice deeper levels of sedation – sedation is titrated according to the type 
of procedure.  Supporters of procedural sedation however claim, and rightly so, that nobody 
should be allowed to practice sedation without adequate training and experience.   
 
In children, especially, it is widely believed that conscious sedation is not always possible – 
in fact it is called by some physicians a myth.  Children can also easily slip unintentionally 
into a deeper level of sedation.  Therefore we have to be very diligent and watchful when 
we sedate children.  The use of monitoring equipment is essential according to sedation 
guidelines when we sedate children.   
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It is therefore of critical importance that research studies be done to evaluate sedation 
techniques, as paediatric sedation is becoming a very important part of patient care.  In fact, 
paediatric sedation is one of the fastest growing areas in anaesthesia care.   
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CHAPTER TWO 
 
SEDATION IN A NUTSHELL 
 
2.1 THE HISTORY OF SEDATION 
 
Craig and Skelly (2004:1) stated that dentists played a huge role in the development of 
general anaesthesia and later also in the introduction of local anaesthesia and conscious 
sedation.  As early as 1844 Horace Wells used nitrous oxide for the first time, and in 1846 
William Morton used ether for dental extractions (Craig & Skelly 2004:2).  Reports that 
dentists used nitrous oxide for conscious sedation appeared in the early 1900s (Craig & 
Skelly 2004:2).   In 1904 procaine was available for use in dental patients.  Lignocaine 
followed in the late 1940’s.   
 
Through the years with the development of various different drugs the techniques used for  
conscious sedation developed.  Today, paediatric sedation is one of the components of 
anaesthesia that is developing the fastest.  The barbiturates were developed as follows: 
1912 phenobarbitone, the 1930s hexobarbitone and thiopentone, the 1960s intravenous 
methohexitone (Craig & Skelly 2004:3).  The next very important drug that became 
available was propofol in 1977 (Craig & Skelly 2004:6).  One of the most important 
benzodiazepines that we use today is midazolam that became available in 1983 (Craig & 
Skelly 2004:6).   
 
With the development of pulse oximetry and portable monitoring equipment, the practice of 
sedation outside of the operating room became a safer option to many patients.   
 
2.2 DEFINITIONS OF SEDATION 
 
There are different levels of sedation. It is important for every sedation practitioner to 
understand this, as levels of sedation in actual fact means the level of consciousness.  These 
levels of sedation are on a continuum which begins with anxiolysis (minimal sedation) and 
end with general anaesthesia.  Patients can easily unintentionally slip from one level of 
sedation into another, and this is especially true in children.  This means that medical 
personnel performing sedation on children should be trained to evaluate and recognize the 
different levels of sedation, and also be vigilant in monitoring while doing sedation.   
 
A paediatric sedation programme at the University of Wisconsin Children’s Hospital 
(2008) and lecture notes of Dr. M. Jansen van Rensburg (2007), and Prof. J. Roelofse, 
explains the following terms:   
Mild sedation/anxiolysis: This is a drug induced state where the patient can respond 
normally to verbal commands.  Respiratory and cardiovascular functions remain 
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unimpaired.  There may be mild alteration to gross motor function. Clinical monitoring of 
the patient is all that is necessary.   
Moderate sedation and analgesia: In the past this level was referred to as conscious 
sedation.  This is a drug induced depression of consciousness.  The patients can still 
maintain their airway adequately, and respond to verbal commands or light tactile 
stimulation.  Cardiovascular function is maintained.   
Dissociative sedation: This is another term in sedation which is used specifically when 
ketamine is used to perform the sedation.  The patients are in a trans-like cataleptic state.  
Protective airway reflexes and breathing are intact. Patients have analgesia, sedation, 
amnesia, without loss of consciousness. It is believed that this level of sedation is different 
to any level that we define on the sedation continuum.   
Procedural sedation and analgesia: Procedural sedation should be viewed as a continuum 
of sedation levels ranging from light to deep sedation.  Sedative, hypnotic, analgesic and 
dissociative drugs are used to provide anxiolysis, analgesia, sedation and motor control.  
The depth of sedation can easily be titrated by selective administration of sedatives and 
analgesics.  The term procedural sedation is used by some physicians to practice deeper 
levels of sedation – sedation is titrated according to the type of procedure.   
Deep sedation and analgesia: This is also a drug induced depression of consciousness, 
where the patient responds purposefully to repeated or painful stimulation.  Spontaneous 
ventilation may be inadequate and patients may require assistance in maintaining their 
airway.  Cardiovascular function is usually maintained.  There is diminished muscle tone.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 5 
2.3 THE CONTINUUM OF SEDATION 
 
Graphic explanation of the sedation continuum (in conversation with Prof. J. Roelofse). 
 
It is important to realise that sedation is a continuum that starts with anxiolysis (minimal 
sedation and analgesia) and ends with general anaesthesia.  There are different levels of 
sedation and children can very easily slip from one level to a deeper level.  To ensure the 
level of the patient, stimulation/verbal commands may be necessary.  Unfortunately we do 
not want to disturb a child in the middle of a procedure because this will influence the 
surgeon in performing the procedure.   For this reason a sedation practitioner needs to be 
trained to be able to recognize the depth of sedation without disturbing the child.  The level 
of sedation, whether it be moderate sedation or any other level of procedural sedation, must 
be evaluated by the sedation practitioner according to the procedure done and the co-
operation of the child.   
 
 Deep sedation might not always be a safe option outside of the operating room, but the 
sedation practitioner must be able to rescue a child who slips into deep sedation 
unintentionally.   
 
In an article by Cotè, Notterman, Karl, Weinberg and McCloskey (2000), the authors found 
that the biggest contributing factor to morbidity and mortality when sedating children is a 
failure to rescue.   
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2.4 LITERATURE REVIEW 
 
Over the years the sedation practice outside of the operating theatre has become a very 
contentious subject.  From all over the world articles on this topic have begun to appear in 
medical and dental journals, and on the internet.  The researcher will discuss a few of these 
articles to emphasize important factors concerning sedation.   
 
Cotè (1994) mentions different organizations in the United States that each have protocols 
for sedation.  He states that some of the protocols have been written for the convenience of 
the practitioners practising sedation, and not for the safety of the patients.  The Committee 
on Drugs (COD) of the American Academy of Paediatrics (AAP) has spent considerable 
time addressing the difficult issue of appropriate care for sedated paediatric patients.  They 
emphasized the importance of monitoring, medical evaluation of the patient’s condition, 
clinical skills, pre- and post-sedation evaluation, and the nil per os status of the patient.   
Cotè (1994) stated that the most important goal of the guidelines by the AAP has been 
accomplished by stirring the debate of discussion concerning the topic of the safety of 
paediatric sedation.   
 
The purpose of the study by Roelofse, Joubert and Roelofse (1996) was to evaluate a new 
sedation technique for children having dental procedures.  One hundred patients were 
included in this study.  Fifty received midazolam alone, and fifty received a combination of 
midazolam and ketamine rectally.  The conclusion was that both methods are safe and 
effective in sedating children, although the incidence of hallucinations in the midazolam 
group was markedly increased.   
 
The study of Gremse, Kumar and Sacks (1997) retrospectively reviewed the medical 
records of 116 patients receiving sedation.  They were divided in 2 groups.  The one group 
received midazolam less than 0.3mg/kg and the second group received midazolam more 
than 0.3mg/kg.  Meperidine 1mg/kg was used with the midazolam.  The authors found both 
regimes were highly successful.  Even with the higher dosage of midazolam there were no 
complications or adverse events in their study.  They stated that for safe and effective 
intravenous sedation personnel are required who are experienced in paediatric sedation.  
Monitoring is essential and paediatric resuscitation equipment should be available.   
 
In the study of Egelhoff, Ball, Koch and Parks (1997), 6006 paediatric outpatients in a 
radiology department were retrospectively reviewed for safety and efficacy of sedation.  
Sedation guidelines from the AAP were used.  They reported no serious complications or 
adverse events.  Minimal interventions were required for complications that occurred.  
They had a one percent failure rate.  They concluded that sedation can be done in a safe and 
efficacious manner in a radiology department for children.   
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Morton and Oomen (1998) developed a selection and monitoring protocol for sedation in 
children.  A survey in Scotland found that only 3 out of 38 hospital departments, which 
sedate children, had a formal protocol for paediatric sedation.  The principles underlying 
the protocol concerned the following: informed consent, fasting guidelines, contra-
indications to sedation, monitoring, trained personnel and discharge criteria.   
 
In the study of Pena and Krauss (1999), 1180 patients were sedated with different 
medication regimes in an emergency department over a period of one year.  No serious 
morbidity or mortality was documented.  The conclusion was that emergency physicians 
practised procedural sedation safely.   
 
In the study of Havel, Strait and Hennes (1999), 91 patients were enrolled.  The authors 
found the drugs comparable in efficacy and adverse events.  In the propofol group, the 
recovery time was shorter.   
 
The article by Krauss and Green (2000) gives general information about sedation and how 
it should be done.  Clinical monitoring is seen as very important.  The pharmacology of 
drugs being used in sedation is discussed.  The new ultra short-acting drugs are mentioned 
and discussed.  The authors also state that further research is necessary to evaluate drugs 
like propofol and remifentanil in the practise of paediatric sedation.   
 
Coté, et al. (2000) reviewed 95 cases where serious adverse events occurred in paediatric 
sedation.  Their conclusion was that the morbidity and mortality found in this study was 
due to the following factors: inadequate monitoring, errors in managing complications, 
inadequate pre-procedure medical evaluation, medication errors, inadequate recovery 
procedures, and the lack of an independent observer.  They state most of these 
complications could have been prevented.   
 
In the study of Hoffman, Nowakowski, Troshynski, Berens and Weisman (2002), the 
authors tested the hypothesis that application of an AAP/ASA-structured model would 
reduce the risk of sedation-related adverse events.  Their conclusions were that the use of 
these guidelines by non-anaesthesiologists does reduce the risk of adverse events in 
paediatric sedation.   
 
Two regimens of sedation medications were compared in the study by Godambe, Elliott, 
Matheny and Pershad (2003).  One hundred and thirteen patients between the ages of 3 and 
18 were included in this study.  The authors conclude that although propofol has a greater 
potential for respiratory depression and airway obstruction as compared to ketamine, it 
offers unique advantages including a quicker onset, and smoother recovery profile.   
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Pitette, Singh and Pierce (2003) studied 1244 sedation procedures in 1215 patients.  The 
incidence of complications related to procedural sedation was 17.9%.  All the 
complications were easily treated and no serious adverse events took place.  Sedation was 
successful in 98.6% of patients.  The authors concluded that procedural sedation and 
analgesia can be safely and effectively provided by non-anaesthesiologists.   
 
The review article by Cravero and Blike (2004) looked at the historical role of 
anaesthesiologists in the practice of paediatric sedation.  The author further writes about the 
current status and trends of sedation practice.  Safety issues are also discussed, as well as 
the need for further research and developing of guidelines to practice safe and efficacious 
sedation.   
 
The literature concerning the efficacy and safety of ketamine for sedation during 
procedures in paediatric emergency departments was reviewed by Mistry and Nahata 
(2005).  The term dissociative sedation is used in this article.  The conclusion was that 
ketamine is a safe drug to use in the sedation of children by those who are trained to use 
this drug.   
 
The objective of the study by Roback, Wathen, Bajaj and Bothner (2005) was to compare 
the frequency and severity of adverse events associated with different drug regimes.  The 
incidence of adverse events in this study was 17%.  Certain drug regimes were associated 
with specific adverse events.  Ketamine with or without midazolam had a higher incidence 
of nausea and vomiting.  Midazolam and fentanyl were more likely to give respiratory 
adverse events.   
 
In this study by Sanborn, Michna, Zurakowski, Burrows, Fontaine, Conner and Mason 
(2005) the incidence of respiratory adverse events was much lower, at 0.4%, if compared to 
the study of Roback et al. (2005).  The authors attribute this fact to the training and 
experience of their personnel.  They also mention that a history of respiratory illness could 
increase the risk of an adverse respiratory event.   
 
Blike, Christoffersen, Cravero, Andeweg and Jensen (2005) developed a single scenario of 
a possible adverse event with the technology of a human simulator.  The scenario was 
reproducible with realistic physiology that degraded over time if no interventions occurred 
and improved when treated appropriately.  Sedation teams from the radiology and 
emergency departments were evaluated to identify latent system errors.  This study 
measured rescue capability and revealed vulnerabilities in personnel structure and in care 
systems.   
 
Sadhasivam, Ganesh, Robison, Kaye and Watcha (2006) in their study concluded that the 
bispectral index monitor (BIS) is an objective and non-disruptive tool for measuring the 
depth of sedation in children older than one year, and who did not receive ketamine.  Not 
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everybody agrees with this finding as not many studies have validated the use of the BIS 
monitor to measure the depth of sedation. 
 
Coté, Wilson and the Work group on sedation (2006) updated the guidelines on paediatric 
sedation.  This was a joint effort between the AAP and the American Academy of 
Paediatric Dentistry (AAPD).  This article includes comprehensive guidelines about 
paediatric sedation from the pre-operative assessment to discharge of the patient.   
 
The study objective of Anderson, Junkins, Pribble and Guenther (2007) was to evaluate the 
relationship between continuous capnography and observed airway and respiratory adverse 
events, and the depth of propofol sedation for paediatric orthopaedic procedures.  Their 
conclusion was that capnography detects most airway and respiratory events leading to 
intervention before clinical diagnosis or pulse oximetry.   
 
The article on pharmacologic behaviour management by Kerins, McWhorter and Seale 
(2007) was a mailed survey to dentists in Texas.  The conclusion was that they treat an 
increasing number of patients with ADD (Attention Deficit Disorder) and ADHD 
(Attention Deficit Hyperactivity Disorder).  The dentists reported using a wide variety of 
pharmacologic management techniques.  They supported the creation of guidelines to better 
manage this group of patients.   
 
In 2001 Yagiela published an article to advocate the use of office- based sedation for a 
variety of patient groups that need dental treatment.  These patients included all patients 
who are nervous or even terrified of dental appointments, young children, the behaviourally 
or medically challenged, and individuals who are undergoing extensive procedures or have 
problems with gagging or local anaesthesia.  The article concluded that the different 
methods that were discussed can provide complementary benefits to both the patient and 
the treating dentist.   
 
A very important question was raised by Flick and Clayhold (1998), namely who should 
determine the medical necessity of dental sedation and general anaesthesia?  In the 
financially driven world we live in, this can be very frustrating when treating patients are 
secondary to financial concerns.   
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CHAPTER THREE 
 
PHARMACOLOGY OF DRUGS USED 
 
3.1 INTRODUCTION 
 
The administration of drugs plays an important part in the safety of patients during 
procedural sedation and analgesia.  Pharmacologic principles involve the pharmacokinetics 
and pharmacodynamics of drugs.  Any sedation practitioner must have a clear 
understanding of pharmacologic principles concerning drugs.  The pharmacokinetics and 
pharmacodynamics of drugs will be discussed according to Sommers (2000:353-366) and 
Morgan and Mikhail (1996:128-132).   
 
3.1.1 PHARMACOKINETICS is the “study of the relationship between a drug’s dosage, 
tissue concentration, and time since administration.”(Morgan & Mikhail 1996:128) Simply 
put, it describes how the body affects a drug.  This can be divided in the following 
parameters:   
 
• Absorption,  
• Distribution,  
• Metabolism and  
• Excretion.   
 
ABSORPTION:  Absorption is the physical passing of drugs from the outside to the inside 
of the body thus reaching the blood stream.  Morgan and Mikhail (1996:128) describes 
absorption as the process by which a drug leaves its site of administration to enter the blood 
stream. 
 
Different routes of administration are possible to use: oral, nasal, sublingual, transdermal, 
rectal, and parental.   
• With oral administration, the majority of all absorption occurs in the intestines, 
where drugs must pass through the intestinal wall to enter the blood.  It is important 
to distinguish between those interactions in which the rate of absorption is altered 
and those in which the total amount absorbed are altered.  With oral administration 
there is also the first-pass hepatic metabolism that influences the bio-availability of 
drugs. It simply means that not all of the drug taken orally will eventually reach the 
effect site. 
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• Nasal administration of drugs therefore seems a good way of reaching an effective 
plasma concentration.   
 
• Sublingual or buccal administration bypasses the first-pass hepatic metabolism, 
because the veins in the mouth drain directly into the superior vena cava.  This 
means in effect that a bigger concentration of the administered drug is available.   
 
• Transdermal drug administration, rarely used for sedation, has the advantage of 
prolonged and continuous absorption.   
 
• Rectal administration is an alternative route of administration, specifically in 
uncooperative patients.  This way of administration can also be safely used in small 
children.  Absorption from the rectum can be erratic, and can cause irritation of the 
rectal mucosa.  The venous drainage of the rectum also bypasses the liver.   
 
• Parenteral injection can be subcutaneous, intramuscular or intravenous.  
Subcutaneous and intramuscular administration depends on the rate of diffusion, 
and that is dependent on the blood flow to the specific area.  Intravenous 
administration completely bypasses the process of absorption, because it is 
delivered directly into the blood stream.   
 
Hogan, Zucchero, Schultz and Curren (1992) explained the absorption of drugs in a 
practical way as follows: 
• With medications administered chronically, such as Coumadin (warfarin), the rate 
of absorption is usually not important, provided that the total amount absorbed is 
not altered significantly.  For a medication administered as a single dosage and 
intended to be absorbed rapidly, such as analgesics or hypnotics, a high 
concentration needs to be achieved rapidly for efficacy, thus, a reduced absorption 
rate may result in failure to attain adequate serum levels.   
 
• Drug passage through the gastric mucosa is by passive diffusion that depends on the 
amount of drug that is non-ionized.  Absorption can thus be influenced by the pKa 
and lipid solubility of the medication, and the pH of the stomach contents.  Thus, an 
alteration in gastric pH by anti-acids can alter absorption of drugs.   
 
• Medications that alter the rate of gastric emptying and gastro-intestinal motility e.g. 
the opiates also affect drug absorption, as many medications are primarily absorbed 
in the upper part of the small intestines.  Slower gastro-intestinal motility means the 
drug stays in the intestines for a longer period of time and there will be an increase 
in absorption.  Metoclopramide is one drug that decreases the gastro-intestinal 
motility.   
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DISTRIBUTION:  After absorption, drugs need to be delivered to the target area to exert 
their effect.  Distribution refers to the process in which drugs are carried in the blood 
stream and released to different parts of the body.  A drug’s distribution depends primarily 
upon organ perfusion, protein binding, and lipid solubility.  Drug interactions can occur 
during the distribution phase if the drug has a narrow therapeutic index and is highly 
protein-bound.  Protein binding can be a significant source of drug interactions.  Binding to 
plasma proteins is reversible, and equilibrium is established between those drug molecules 
bound and unbound, with only those molecules unbound and in solution being 
pharmacologically active.  The molecules that are bound to plasma proteins are inactive 
and protected from metabolism, and prevented from being excreted.  Albumin often binds 
to acidic drugs like barbiturates, while ∂1-acid glycoprotein (AAG) binds to basic drugs, 
like local anaesthetics.  If a drug is 99% plasma protein bound and another drug reduces 
this binding to 95%, this results in an increase in the unbound drug fraction from 1% to 4%, 
a four-fold increase.  This displacement of drug molecules from protein binding sites to the 
plasma is only likely to increase the number of free molecules significantly if most of the 
unbound drug is in the plasma, instead of within the tissues.  Only medications with a low 
apparent volume of distribution will be affected.   The apparent volume into which a drug 
has been distributed is called its volume of distribution, and is determined by dividing the 
dosage of the drug administered by the resulting plasma concentration.  There are other 
factors that also influence drug distribution, for example the blood-brain barrier and 
redistribution.   
 
METABOLISM:  Most drugs are metabolized by the liver to inactive metabolites.  
Hepatic microsomal enzymes, concentrated mainly in the endothelium of liver cells, change 
the parent molecule.  This is a very important point for sedation practitioners as liver 
disease my decrease the metabolism of drugs e.g. midazolam, with a prolonged action.   
 
Metabolic biotransformation can be divided into phase 1 and phase 2 reactions.  
• Phase 1 reaction convert a parent drug into more polar metabolites through 
oxidation, reduction, or hydrolyses.   
• Phase 2 reactions couple (conjugate) a parent drug or a phase 1 metabolite with a 
endogenous substrate to form a highly polar end product that can be eliminated in 
the urine.  Although this usually happens in sequence, a phase 1 metabolite may be 
excreted without being converted to a phase 2 metabolite, and sometimes phase 2 
can occur first.  In the last stages of metabolism, water-soluble molecules are added 
to the parent molecule to form a large molecule that is water-soluble, inactive and 
readily excreted.   
 
Hepatic clearance is the rate of elimination of a drug as a result of liver bio-transformation.  
The hepatic clearance depends upon the hepatic blood flow and the fraction of the drug 
removed from the blood by the liver.  This is the hepatic extraction ratio.   
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If the liver enzymes were induced to slow down its metabolism, drugs would be inactivated 
at a slower pace and the overall effectiveness of the substance would be higher, and vice 
versa.  In general, drugs that induce liver metabolism do not exert an immediate effect.  The 
rate of liver metabolism changes slowly over several weeks.  Therefore, the effect of 
increased or decreased liver metabolism is not seen until several weeks after the initiation 
of drug therapy.  Some examples of drugs that increase liver metabolism are phenytoin, 
carbamazepine, phenobarbitals, rifampicin, ethanol, tobacco and glucocorticoids.  Patients 
on these drugs might need higher dosages of medication e.g. midazolam to achieve the 
desired level of sedation.  On the other hand, drugs that inhibit liver metabolism have an 
immediate onset of action.  The rate of liver metabolism may be greatly impaired within a 
few days.  Therefore, there is a greater risk of drugs accumulating in the body as the 
function of the liver to inactivate them is compromised.  Examples of drugs that inhibit 
liver metabolism include cimetidine, erythromycin, fluconazole, itraconazole, 
ketoconazole, antivirals, calcium channel blockers and grapefruit juice.  If benzodiazepines 
are used smaller dosages are needed, and drugs should be titrated. 
 
The cytochrome P-450 iso-enzymes are a group of structurally related enzymes that are 
divided into families, subfamilies and genotypes. CYP1, CYP2 and CYP3 appear to be 
involved with drug metabolism.  These families make up approximately 72% of the total 
available CYP.  When two or more medications that share the same metabolic pathway are 
administered concurrently, metabolizing enzyme systems may become saturated, leading to 
a possible decrease in the metabolic rate of one or both medications, with subsequent 
increase in plasma levels.   
 
EXCRETION:   
• The kidneys are the principal organs of excretion.  Non-protein bound drugs freely 
cross from plasma into the glomerular filtrate.  The non-ionized fraction of the drug 
is reabsorbed in the renal tubules, while the ionized portion is excreted.  This means 
that an alteration in the pH of the urine can influence the excretion of drugs.  If the 
kidneys are damaged, the rate of elimination by the kidneys would be slowed down, 
leading to an accumulation of drugs in the body. This is rarely a problem in daily 
sedation practice outside the operating theater as only ASA 1 and 11 patients are 
accepted.  
 
• Very few drugs depend on biliary excretion, since they are reabsorbed in the 
intestine, and then excreted in the urine.  This is called entero-hepatic recirculation, 
and this can be responsible for the delayed toxic reactions that can occur.   
 
• The lungs are responsible for the excretion of volatile agents.   
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3.1.2 PHARMACODYNAMICS refers to the study of how drugs affect the human body.  
The extent of these effects determines a drug’s efficacy, potency and therapeutic ratio.  
Pharmacodynamics describes the mechanism of action, drug interactions, and structure-
activity relationships.  There can be synergistic or antagonistic interaction between drug 
molecules.  These reactions are generally more difficult to predict and prevent than 
pharmacokinetic interactions.   
 
With the above as background, each of the drugs that were used in this research study, will 
be discussed separately.  
 
3.1.3 THE IDEAL SEDATIVE DRUG 
 
One is tempted to ask whether there is an ideal sedative drug. 
According to Craig and Skelly (2004:28) the ideal intravenous sedation agent should have 
the following properties: 
1. The drug should provide anxiolysis, analgesia and amnesia. 
2. A rapid onset of action. 
3. It must be easy to titrate. 
4. The drug must have predictable a sedative and anxiolytic action. 
5. Induction and recovery must be rapid. 
6. No side effects or systemic toxicity. 
7. The speed of change in sedation level must be rapid. 
8. It must be reversible. 
9. Undergo rapid metabolism to inactive metabolites. 
10. The drug must have minimal cardiovascular and respiratory side effects. 
11. The potential for anaphylactic/allergic reactions must be low. 
12. The drug must be water soluble with a long shelf-life at room temperature. 
 
There is no single drug available today that has all these properties.  To achieve this, a 
combination of drugs must be used.  The synergistic effect [1+1=3] plus the additive effect 
[1+1=2] can be used when the sedation practitioner uses a combination drug technique.  
Using more than one drug means that smaller dosages of each individual drug can and 
should  be used.  When using smaller dosages, the potential for side effects is lower.  Even 
when using small dosages, the drugs used must still be titrated to effect in each individual 
patient.   
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3.2 MIDAZOLAM [DORMICUM®] 
 
The discussion of midazolam is based on the approved package insert (Annexure K).   
 
3.2.1 CHEMICAL STRUCTURE 
 
Midazolam is a short acting benzodiazepine that became available in 1983 (Craig & Skelly 
2004:6).  It is a clear, colourless liquid in a glass ampoule.  Midazolam is available in 
5mg/ml (midacum®), 5mg/5ml, 15mg/3ml and 50mg/10ml concentrations.  The ampoules 
can be administered nasally, orally, rectally and intravenously.  There are different dosages 
for each route of administration.  Benzodiazepines have a large therapeutic index and the 
availability of a specific receptor antagonist, flumazenil, makes it reasonably safe to 
administer.  Midazolam is a drug used commonly for sedation procedures.   
 
3.2.2 PHARMACODYNAMICS 
 
Midazolam is a derivative of the imidazo-benzodiazepine group.  The free base is a 
lipophilic substance with a low solubility in water.  The basic nitrogen in position 2 of the 
imidazo-benzodiazepine ring system enables the active substance to form water-soluble 
salts with acids.  Midazolam has different effects depending on the percentage of receptor 
occupancy.  It acts as an anticonvulsant, an anxiolytic and has sedation properties.  
Anterograde amnesia may occur after administration.  In high dosages, midazolam has 
muscle relaxation properties (Sommers 2000:151).   
 
Mechanism of action: The binding site is found on the alpha subunit of the beta2 GABA-
receptor.  These receptors are found in the cerebral cortex, cerebellum, hippocampus, 
substantia nigra, corpus striatum, brainstem and spinal cord.  Midazolam increases the 
permeability of the chloride channels, thus hyperpolarizing the membrane with increased 
resistance to neuron excitation (Sommers 2000:151).    
 
3.2.3 PHARMACOKINETICS 
 
Absorption of midazolam  
• After oral administration is 10 to 30 minutes.   
• After intramuscular injection absorption is rapid and complete.  The maximum 
plasma concentration is reached within 30 minutes, and bio-availability is over 
90%.   
• After buccal, nasal or sublingual administration time to peak effect is 10 to 15 
minutes, and the duration of action is 20 to 60 minutes.   
• Administering Midazolam rectally results in a peak effect in 10 to 20 minutes.   
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• When Midazolam is administered intravenously the time to peak effect is 10 
minutes, and the duration of action is 20 to 60 minutes (SASA sedation guideline 
2010:11).   
 
Distribution: When midazolam is injected intravenously, plasma concentration shows a 
short distribution phase of 5 – 15 minutes, followed by an elimination phase.  Studies show 
a protein binding of 96 – 98%.  
Metabolism: Midazolam is completely metabolized and the primary metabolite is a α-
hydroxy-midazolam.  The fraction extracted by the liver is 40 – 50%.  This active 
metabolite conjugates with glucoronic acid and is then eliminated by the kidneys more 
rapidly than Midazolam. 
 
Elimination: The elimination half life is between 1.5 – 2.5 hours in adults.  In children it is 
shorter, namely 1 – 1.5 hours. About 50 – 70% of midazolam is eliminated by the kidneys 
in the form of a conjugate of the α-hydroxy-metabolite. 
 
3.2.4 DOSAGE AND DIRECTIONS FOR USE 
 
Midazolam is a potent and popular sedative agent that requires slow administration and 
individualisation of dosage.  The dosage should be individualized and titrated to the desired 
state of sedation according to the clinical need, physical status, age and concomitant 
medication of each patient.  Remember that time to peak effect after intravenous 
administration is 10 minutes (SASA sedation guideline 2010:11).   
 
Pre-medication: In children the dosage ranges between 0.25 – 0.5 mg/kg orally with a 
maximum dosage of 7.5mg. 
 
Moderate sedation and analgesia/Conscious sedation: In this study Midazolam was used 
as part of a combination drug sedation technique.  The dosage for intravenous midazolam 
ranges between 0.05 – 0.1mg/kg to a maximum bolus dosage of 2mg.  The recommended 
maximum dosage is 3mg.   
 
Midazolam may also be administered by the following routes (SASA sedation guideline 
2010:11): 
• Orally: 0.25 – 0.5mg/kg with onset of action between 10 – 30 minutes and duration 
of action is 60 minutes.   
• Buccal/sublingual: 0.25 – 0.3mg/kg with time to peak effect 10 – 15 minutes and 
duration of action between 20 – 60 minutes.   
• Per rectum: 0.5 – 0.75mg/kg with time to peak effect 10 – 20 minutes and duration 
of action is 60 minutes.   
• Intranasally: 0.2 – 0.3mg/kg. The time to peak effect is 10 – 15 minutes and the 
duration of action is 20 – 60 minutes.   
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• Intramuscularly: 0.1 – 0.2mg/kg with an onset of action between 5 – 10 minutes. 
 
3.2.5 SIDE EFFECTS AND SPECIAL PRECAUTIONS 
 
• The side-effects most commonly encountered are drowsiness and over-sedation.   
• Less common are depression of mood and affect, disorientation or confusion, 
lethargy and ataxia.   
• Effects like nausea and vomiting, headache, hiccoughs, laryngospasm, dyspnoea 
and hallucinations have also been reported.   
• Double vision can be a problem in smaller children.   
 
Midazolam can be considered a safe agent in the correct sedative dosage, but overdosage 
can cause paradoxical reactions, confusion or life threatening respiratory depression and 
coma.   
 
Flumazenil reverses the sedative and respiratory depressant effects of benzodiazepines.  It 
should be readily available whenever benzodiazepines are used for sedation.  The dosage is 
10µg/kg.  The titration interval is 2 minutes with a maximum dosage of 1mg/kg.  It is 
important to realize that the duration of action is only 1 hour (Sommers 2000:154), which 
means that re-sedation may occur if large dosages of benzodiazepines are administered 
(Sommers 2000:155).  Patients who have taken Midazolam must always be discharged in 
the care of a responsible person.   
 
3.2.6 DRUG INTERACTIONS 
 
The suppression of the central nervous system is increased if used with the following drugs: 
antipsychotics, hypnotics, anxiolytics, anaesthetic drugs, narcotic analgesics, 
antidepressants, antiepileptic drugs, alcohol, and sedative antihistamines.   
 
Drugs that inhibit hepatic enzymes (especially cytochrome P450 III A) can lead to 
increased effect and sedation.  The following drugs are included: cimetidine, ranitidine, 
erythromycin, diltiazem, verapamil, ketoconazsole and itraconozole.   
 
Midazolam potentiates the effect of the opiates.   
 
3.2.7 PERSONAL EXPERIENCE 
 
In my experience the use of Midazolam as pre-medication is essential to facilitate the 
placement of the intravenous cannula.  Many parents find the idea of placing a “needle” on 
the hand of their child very frightening. With the help of midazolam and an EMLA patch, 
this procedure is relatively easy. 
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In this study population, most of the children had a surgical procedure before, which is 
helpful if the parents can give a history of paradoxical reactions to midazolam.  In these 
cases you have to avoid using midazolam.  Hydroxyzine (Aterax®) at a dosage of 
0.6mg/kg could be an alternative in these cases.   
 
The children received 3.75mg (½ a 7.5mg tablet) per os if they were younger than 6 years.  
Children older than 6 years received a full 7.5mg tablet.  Most of the children do not have 
problems swallowing a tablet.  These days most children take vitamins and are used to 
taking tablets.  If they have problems taking the tablet, they should be encouraged to chew 
and swallow with water.  In the few cases who could not take the tablet, the liquid ampoule 
solution was used at a dosage of 0.5mg/kg.  The midazolam liquid was then combined with 
panado or ponstan syrup made up to a volume of 5ml.   
 
With the induction of sedation, a dosage of 0.5mg midazolam was used intravenously.  
Usually this dosage was sufficient with the combination drug technique.  In a few cases 
where it was clear that the child is still anxious, further dosages of 0.5mg were titrated to 
effect.  A further benefit of using midazolam is that it counteracts the possibility of 
hallucinations that can be caused by the use of ketamine.   
 
Midazolam tends to make children disinhibited.  Patients who are of a happy disposition 
tend to be happy, but patients who are of a sad temperament tend to become more morose.  
These patients can be tearful during the procedure, and increasing the dosage of midazolam 
tends to worsen this occurrence (Whitwam & McCloy 1998:134).  I have seen this reaction 
in a few patients, mostly adult females  
 
3.3 PROPOFOL [DIPRIVAN®] 
 
The discussion of propofol is based on the approved package insert (Annexure L).   
 
3.3.1 CHEMICAL STRUCTURE 
 
Propofol is a 2,6 diisopropylphenol which is classified as a sedative-hypnotic with a quick 
onset of action, and recovery.  It is a milk white substance marketed in 20ml glass 
ampoules for single use, and also 50ml vials for infusions as a 1% solution at 10mg/ml.   
 
The formulation at present consists of 1% propofol, soyabean oil, glycerol and egg 
phosphatite.  This means that 1.0 ml of propofol contains 0.1 gram of fat.  This substance is 
an oil emulsion at room temperature.  It is highly fat-soluble.  Propofol is stable at room 
temperature and not sensitive to light.  The pH is 7. The drug is compatible with 5% 
dextrose water.   
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3.3.2 PHARMACODYNAMICS 
 
Propofol has a rapid onset of action of approximately 30 seconds, which makes it an ideal 
drug for sedation practice.   
 
Falls in mean arterial blood pressure and slight changes in heart rate are observed when 
propofol is administered for induction and maintenance of anaesthesia.  Bradycardia and 
hypotension have been reported.  This is rarely a problem with sedation as smaller dosages 
are used.   
 
Respiratory effects are a drop in tidal volume, but increase in respiratory rate.  When using 
propofol as an anaesthetic induction agent at a dosage of 1.5 – 2.5mg/kg, respiratory 
depression can occur.   This is not the dosages used for induction of sedation.   
 
Propofol reduces cerebral blood flow, intracranial pressure and cerebral metabolism.   
Recovery from anaesthesia and sedation is usually rapid and the patients are clearheaded 
within 2 – 8 minutes.  This is an ideal characteristic for sedation as patients can return 
home soon after the operation.   
Propofol has anti-emetic properties, and can also act as an anti-pruritic.  It must be noted 
that propofol has no analgesic properties, therefore analgesics have to be added to any 
sedation regime if the procedure is painful.   
 
Mechanism of action: The mechanism of action is poorly understood, but it may involve 
facilitation of inhibitory neurotransmission mediated by γ-aminobutyric acid.   
 
3.3.3 PHARMACOKINETICS 
 
Absorption: Propofol can only be administered intravenously and is highly fat soluble.  
The sedation induction dosage of propofol is 0.5mg/kg.  The onset of action is 45 - 90 
seconds if the titration interval is 1 minute (SASA sedation guideline 2010:12-13).  
Propofol metabolism can be described by a three compartment model (Whitwam & 
McCloy 1998:27).   
 
Distribution: The distribution half -life of propofol is 2 – 4 minutes, which is the first part 
of the three compartment model.  In order to maintain sedation at a constant level, it is 
therefore desirable to administer propofol by a continuous infusion technique (Craig & 
Skelly 2004:39).   
 
Metabolism: The second phase is a rapid metabolism [half-life of 30 – 60 minutes], with a 
slower final phase [184 – 502 minutes] of redistribution from poorly perfused tissue 
(Whitwam & McCloy 1998:27).  Propofol is metabolized in the liver, but the high 
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clearance rate of 2 liters/minute implicates the existence of extra hepatic metabolism.  
Inactive conjugates are formed (Morgan & Mikhail 1996:145).   
 
Elimination: An inactive metabolite of propofol is excreted in the urine. The 
pharmacokinetics is linear over the recommended range of infusion rates of propofol.   
With the usual maintenance regimes no significant accumulation of propofol occurs.   
 
3.3.4 DOSAGE AND DIRECTIONS FOR USE 
 
Propofol has a narrow margin of safety, therefore only an experienced sedation practitioner  
skilled in airway management should administer propofol.  It must not be used if the 
operator is also the sedation practitioner (SASA sedation guideline 2010:12).  However, 
there are single operator sedation practitioners e.g. endoscopists who use propofol for 
sedation.   
 
Propofol is not recommended for sedation for children under 3 years of age.  The dosage 
required decreases with the increase in age.   
• The general dosage for induction of anaesthesia is 1.5 – 2.5mg/kg by slow bolus 
injection, titrated against the response of the patient until clinical signs show onset 
of anaesthesia.   
• The dosing schedule according to the SASA sedation guidelines (2010:12) when 
using propofol for sedation is as follows: the induction bolus dosage is 0.5mg/kg.  
The onset of action is 45 – 90 seconds with duration of action of 5 – 8 minutes.   
• When using intravenous infusions for sedation the rate of administration is 2 – 
4mg/kg/h, titrated to clinical effect.  With target controlled infusions the effect site 
concentration should be between 1 - 2µg/ml.   
• In elderly and debilitated patients the dosage of propofol should be reduced.   
 
3.3.5 SIDE EFFECTS AND SPECIAL PRECAUTIONS 
 
• Cardiovascular side effects that occur commonly with propofol use are tachycardia, 
hypotension, flushing and hypertension.  This is rare during sedation. 
• Nervous system side effects include involuntary movements and excitation.  
Epileptiform movements including convulsions and opisthotonos have rarely been 
reported.   
• Common respiratory side effects are apnoea, hiccup, and coughing when propofol is 
used in anaesthetic dosages.   
• Local pain at the injection site is a very common side effect.  The manufacturers 
recommend the co-administration of lignocaine, or the use of a bigger vein on the 
forearm or the cubital fossa.  Tramadol is also used to prevent pain.  
• Anaphylaxis has been reported but is very rare.   
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• Propofol is contra-indicated in patients with egg and soy allergies.  The egg yolk is 
used in manufacturing propofol, but most egg allergies is to egg white (Morgan & 
Mikhail 1996:145).   
• Propofol is preservative free and it is a lipid emulsion, which make it an ideal 
bacterial growth medium.  For this reason all unused propofol must be discarded 
after six hours.   
• Respiration must be monitored to ensure adequate gas exchange.  Special care 
should be taken if propofol is used together with other respiratory depressants like 
the opiates and benzodiazepines.   
 
3.3.6 PROPOFOL INFUSION SYNDROME (PRIS)  
 
This condition is an adverse drug event associated with high dosages and long-term use of 
propofol.  This was reported in critically ill children at first, but recently several cases have 
been reported in adult patients as well.  The priming factor is critical illness.  The triggering 
factors are high dosage propofol (>4mg/kg/h and >48 hours duration), glucocorticoids and 
catecholamines.  The presenting symptoms are severe metabolic acidosis, rhabdomyolysis, 
hyperkalemia, lipemia, renal failure, hepatomegaly and cardiovascular collapse.  To 
improve the outcome of this potentially fatal disease, early recognition and discontinuation 
of the propofol infusion is essential (Zaccheo & Bucher 2008).   
 
3.3.7 DRUG INTERACTIONS 
 
Fentanyl and alfentanil concentrations may be increased by concomitant administration of 
propofol.  Special care should be used when propofol is used together with other respiratory 
depressants like the benzodiazepines and the opiates.   
 
3.3.8 PERSONAL EXPERIENCE 
 
In this study, propofol was used successfully as a continuous infusion as part of a multidrug 
regime with no adverse events or an escalation in care.   
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3.4 GLYCOPYRROLATE [ROBINUL®] 
 
The discussion of glycopyrrolate is based on the approved package insert (Annexure M).   
 
3.4.1 CHEMICAL STRUCTURE 
 
Glycopyrrolate is classified as an anticholinergic (antisialogue) agent.  It is a synthetic 
quaternary ammonium containing mandelic acid in the place of tropic acid (Morgan and 
Mikhail 1996:174).   Glycopyrrolate is presented in 1ml and 2ml clear glass ampoules.  The 
clear liquid contains 0.2mg/ml of glycopyrrolate.  Chlorbutanol 0.5% is added as a 
preservative.   
 
3.4.2 PHARMACODYNAMICS 
 
Glycopyrrolate, like other anticholinergic agents, inhibits the action of acetylcholine on 
structures innervated by postganglionic, cholinergic nerves and on smooth muscle that 
respond to acetylcholine, but lacks cholinergic innervations.   
 
The peripheral cholinergic receptors are present in the autonomic effector cells of smooth 
muscle, cardiac muscle, the sino-atrial node, the atrio-ventricular node, exocrine glands and 
to a limited degree in the autonomic ganglia.  Therefore, glycopyrrolate diminishes the 
volume and free acidity of gastric secretions and controls excessive pharyngeal, tracheal 
and bronchial secretions.  Glycopyrrolate antagonizes muscarinic symptoms such as 
bronchospasm, bradycardia and intestinal hypermotility induced by cholinergic drugs.   
Glycopyrrolate has a highly polar quaternary ammonium group in its structure, which limits 
its passage over lipid membranes, such as the blood brain barrier.  In contrast, atropine has 
a non-polar tertiary amine which penetrates lipid barriers e.g. the blood brain barrier easily.   
 
3.4.3 PHARMACOKINETICS 
 
Absorption:  With intravenous injection, the onset of action is generally evident within one 
minute.  After intramuscular or subcutaneous injection, peak effects occur after 30 to 45 
minutes.   
 
Elimination: Glycopyrrolate is excreted in the bile and urine.   
 
3.4.4 DOSAGE AND DIRECTIONS FOR USE 
 
• Glycopyrrolate can be administered intramuscularly, intravenously or 
subcutaneously.   
• The recommended dosage in children up to twelve years when used as a pre-
anaesthetic medication is 0.004 – 0.008mg/kg (0.02 to 0.04ml/kg) intramuscularly.   
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• For use intra-operatively to block vagal responses, a single dosage of 0.1mg (0.5ml) 
should be given intravenously.  This dosage can be repeated at intervals of 2 – 3 
minutes when necessary.   
• Peak effects occur approximately 30 to 45 minutes after subcutaneous or 
intramuscular administration.  The vagal blocking effects persist for 2 to 3 hours 
and the antisialogogue effects persist for up to 7 hours.   
 
3.4.5 SIDE EFFECTS AND SPECIAL PRECAUTIONS 
 
• Side effects in general may include a dry mouth, urinary hesitancy, blurred vision, 
tachycardia and palpitations.   
• Glycopyrrolate should be used with caution in patients with myasthenia gravis, 
coronary artery disease, congestive heart failure and hypertension.   
 
3.4.6 PERSONAL EXPERIENCE 
 
Glycopyrrolate is useful in paediatric sedation to block the vagal effect of alfentanil and 
reduce the secretions caused by ketamine.  There is not agreement whether all patients 
should receive an antisialogue for sedation. It has been reported that there is a higher 
incidence of respiratory complications when this drug is used with ketamine.  The author 
has not noted this in this research study.   
 
3.5 KETAMINE 
 
The discussion of ketamine is based on the approved package insert (Annexure N).   
 
3.5.1 CHEMICAL STRUCTURE 
 
Ketamine is a phencyclidine derivative and was introduced for clinical use in 1970.  It is a 
noncompetitive N-methyl-D-aspartate glutamate (NMDA) receptor antagonist  (Roelofse 
2010).  The NMDA receptor is important for memory.   
 
Ketamine is presented as a hydrochloride salt made isotonic with sodium chloride.  
Ketamine is presented in three different strengths.  In South-Africa the rasemic mixture is 
available in vials containing 10mg/ml [20ml vial], 50mg/ml [10ml vial], and 100mg/ml 
[10ml vial].   
 
The commercial preparation of ketamine is a racemic mixture of two enantiomers, S (+) 
and R (-).  The enantiomers exhibit pharmacologic and clinical differences.  The S (+) 
enantiomers, marketed as ketanest® but not available in South Africa, has four times the 
potency of the R (-) enantiomers (ketamine®) and twice the analgesic potency of the 
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racemate.  The S (+) isomer appears to be cleared more rapidly, resulting in a shorter 
duration of action and a faster offset, which allow for easier titration when using an 
infusion (Roelofse 2010).   
 
3.5.2 PHARMACODYNAMICS 
 
Ketamine is best described as a “Dissociative Sedation” drug.  Ketamine dissociation 
occurs with maintenance of respiration and a patent airway probably because its primary 
site of action is the cerebral cortex and limbic systems and not the brainstem.  No dosage-
response continuum is observed with ketamine when used for procedural sedation and 
patients are either dissociated or they are not (Howes 2004).   
 
Krauss and Green (2000:941) defined dissociative sedation thus: “A trancelike cataleptic 
state characterized by profound analgesia and amnesia, with retention of protective airway 
reflexes, spontaneous respirations, and cardiopulmonary stability.”    
 
Ketamine has cardiovascular effects, which are due to the central stimulation of the 
sympathetic nervous system.  These effects are increases in arterial blood pressure, heart 
rate and cardiac output (Morgan & Mikhail 1996:143).  Myocardial oxygen demand 
increases as well as myocardial sensitivity to adrenaline.  This is of clinical significance 
especially in dental sedation cases where local anaesthetic agents containing adrenaline are 
used.   
 
Rapid administration of ketamine may cause respiratory depression (SASA sedation 
guideline 2010:13).  When sedative dosages are used and ketamine boluses are given 
slowly, airway patency and respiration will be intact (Howes 2004:275).  Ketamine 
stimulates the production of saliva and trachea-bronchial secretions.  This side-effect can be 
diminished by administering an antisialogogue like glycopyrrolate (Morgan & Mikhail 
1006:143).   
Emergence delirium may be associated with the use of ketamine.  Midazolam can be co-
administered (≤0.05mg/kg) to reduce the incidence further, but will deepen and prolong 
sedation and increase the probability of apnoea.  Ketamine increases cerebral oxygen 
consumption, cerebral blood flow and intracranial pressure.  It also increases ocular 
pressure.   
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3.5.3 PHARMACOKINETICS 
 
The pharmacokinetic findings were consistent with a two-compartment model for 
intravenous administration of the rasemic ketamine (Roelofse 2010).   
 
Absorption: Ketamine has high lipid solubility.  Only 12 – 27% is bound to albumin, 
which allows a rapid transfer across the blood-brain barrier and placenta (Whitwam & 
McCloy 1998:31).   
 
Ketamine can be administered through almost any route (SASA sedation guideline 
20102:13).   
• Oral administration results in peak effect within 30 minutes.   
• Intravenous ketamine has an onset of action of < 1 minute and time to peak effect of 
3 – 5 minutes.   
• Intramuscular and nasal administration takes 20 minutes to reach peak effect.   
• Rectal administration takes 30 minutes to peak effect which is dosage related.   
 
Distribution: The distribution half-life is 10 – 15 minutes.  Awakening is due to 
redistribution to peripheral compartments (Morgan & Mikhail 1996:143).   
 
Metabolism: Ketamine is metabolized in the liver to several metabolites.  One of the 
metabolites, norketamine, has weak hypnotic properties but prolongs analgesia for another 
4 hours.  Hepatic dysfunction may elevate plasma levels and delay elimination. (Whitwam 
& McCloy 1998:31)   
 
Elimination: The elimination half-life is 2 hours.  Ketamine is excreted through the 
kidneys.   
 
3.5.4 DOSAGE AND DIRECTIONS FOR USE 
 
Pre-medication: In this study, ketamine was used as an oral pre-medication in children 
that was not co-operative after the midazolam pre-medication.  The dosage was 2mg/kg.  
This is the dose used when combined with other sedatives and analgesics.   
 
Conscious (moderate) sedation: Ketamine may also be administered by the following 
routes: (SASA sedation guidelines 2010:13)   
• Orally: When ketamine is administered as a single agent orally, the dosage is 4 – 
6mg/kg.  The onset of action is more than 5 minutes, time to peak effect is 30 
minutes and duration of action is 4 – 6 hours.  The drug has a bad taste and must be 
disguised with panado or ponstan syrup.   
• Intravenous: 0.5 – 1mg/kg with onset of action <1minute.  The time to peak effect is 
3 – 5 minutes and the duration of action is 5 – 10 minutes.   
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• Intramuscular: 2 – 4mg/kg with the onset of action between 2 – 5 minutes.  Time to 
peak effect is 20 minutes and the duration of action is 30 minutes.  There is however 
a higher incidence of nausea and vomiting after intramuscular ketamine 
administration. 
• Per rectum: 4 – 6mg/kg with onset of action >5minutes.  Time to peak effect is 30 
minutes and duration of action is 30 – 120 minutes.   
• Intranasally: 5mg/kg with onset of action of 10 minutes.  Time to peak effect is 20 
minutes and duration of action is 1 hour.  This route is not recommended because it 
can be distressing for the patient.   
 
3.5.5 SIDE EFFECTS AND SPECIAL PRECAUTIONS 
 
• Emergence reactions in recovery are common, including vivid and often unpleasant 
dreams, confusion, hallucinations and irrational behavior.  Children appear to be 
less sensitive. The incidence of emergence reactions is controversial; it is probably 
related to the dosage of ketamine administered.  
• Patients may also experience increased muscle tone which is not really a problem 
during sedation.   
• Blood pressure and heart rate may be temporarily increased by ketamine.   
• Respiration may be depressed, especially during too rapid intravenous injection.  
Apnoea and laryngospasm have occurred.   
• Diplopia and nystagmus may occur. It is good practice to especially warn the 
parents of children about this; they can be very upset if the child complains that 
he/she cannot see.  
• Nausea and vomiting, lachrymation and hypersalivation have been reported but 
seem to be dosage-related.   
• Raised intra-ocular and cerebrospinal fluid pressure has also been reported.  It is 
however highly unlikely that ketamine will raise the intracranial pressure in the 
dosages used. 
• Transient skin rashes and pain at the injection site can occur.   
 
 The following special precautions should be adhered to when ketamine is administered for 
sedation:   
• The necessary equipment for airway support, intubation and resuscitation should 
always be readily available.   
•  Patients with a history of epilepsy, psychiatric illnesses or porphyria. There are 
however reports of using ketamine for status epilepticus.   
• Cardiac function should be monitored in patients with mild hypertension or cardiac 
decompensation.   
• Verbal, tactile and visual stimuli should be kept to a minimum during recovery in an 
attempt to reduce the risk of emergence reactions.   
 
 
 
 
 27 
• Don’t inject ketamine rapidly with intravenous administration. 
• Make certain patients are not using ketamine for recreational purposes. 
 
3.5.6 DRUG INTERACTIONS 
 
The combination of theophylline and ketamine may predispose patients to seizures.  
Ketamine produces myocardial depression when given to patients anaesthetized with 
halothane, or to a lesser extent, other volatile anesthetics (Morgan & Mikhail 1006:143).  
This is however not seen when ketamine is used as a sedative agent.   
 
3.5.7 PERSONAL EXPERIENCE 
 
Ketamine is a remarkable and versatile drug that has in recent years made a comeback in 
clinical practice.  The fact that it can be given orally as part of a pre-medication regime, 
means that even the most anxious of children can be sedated without traumatizing them 
with the IV procedure.  The author uses ketamine as a second pre-medication agent 
specifically in children where the placement of the intravenous line is difficult.  The state of 
dissociative sedation that is achieved with ketamine use is beneficial in children.  The 
dissociative state means that you have a relaxed and co-operative child without losing the 
protective reflexes. In this state there is analgesia, sedation, amnesia and minimal effects on 
the cardiovascular and respiratory systems.  The unique qualities of ketamine as previously 
discussed, make ketamine an ideal sedation drug if all the guidelines as to administration 
are followed.   
 
3.6 SUFENTANIL [SUFENTA®] 
 
The discussion of sufentanil is based on the approved package insert (Annexure O) 
 
3.6.1 CHEMICAL STRUCTURE 
Sufentanil is an extremely potent short acting opioid analgesic related to fentanyl.  It is a 
clear, colourless liquid in a glass ampoule.  Each milliliter contains 0.005mg of sufentanil 
and 9.0mg sodium chloride in water for injection.  Sufentanil is available in 2ml and 10ml 
see-through glass ampoules.  Opioids can be classified by either their chemical structure or 
action on receptors.  Sufentanil falls in the group of phenylpiperidines.   
 
3.6.2 PHARMACODYNAMICS 
 
Sufentanil is a mu (µ) opioid agonist with hypnotic properties.  Intravenous sufentanil 
produces a dosage-related attenuation of catecholamine release, particularly noradrenaline.  
When used in balanced general anaesthesia, it is 5 – 10 times as potent as fentanyl.  
Sufentanil is twice as lipophilic as fentanyl and is rapidly absorbed from the nasal mucosa 
(SASA sedation guideline 2010:14).   
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Mechanism of action: Opioids bind to specific receptors located throughout the central 
nervous system and other tissues.  Four major types of opioid receptors have been 
identified, namely mu (µ, with subtypes µ-1 and µ-2), kappa (κ), delta (δ) and sigma (σ).  
Opioids provide some degree of sedation which is in effect a side -effect, but they are most 
effective at producing analgesia.  The agonists are capable of receptor activation.  Opioid-
receptor activation inhibits the presynaptic release and postsynaptic response to excitatory 
neurotransmitters (Morgan & Mikhail 1996:137).   
 
3.6.3 PHARMACOKINETICS 
 
Absorption: Sufentanil is usually given intravenously as adjunct to general anaesthesia in a 
dosage of 0.25 – 30µg/kg (Morgan & Mikhail 1996:141).  It has a rapid onset of action and 
short duration of action which is an advantage when being used in procedural sedation and 
analgesia.   
• After bolus intravenous administration the time to peak effect is 5.6 minutes and the 
duration of action is 30 minutes.   
• Sufentanil can also be used as a continuous infusion.  The time to peak effect with 
an infusion is 6.5 minutes and the duration of action is 240 minutes after a 2 hour 
infusion (SASA sedation guidelines 2010:14).   
• Sufentanil can also be administered intranasally at a dosage of 1.5 – 3.0µg/kg 
(SASA sedation guidelines 2010:14).   
 
Distribution: The pharmacokinetics of intravenous sufentanil can be described as a three-
compartment model with an average distribution time of 0.72 minutes, and a redistribution 
time of 13.7 minutes.  Plasma protein binding is approximately 92.5%.  Redistribution 
terminates the action of small dosages, while larger dosages must depend on 
biotransformation to adequately lower plasma levels.   
 
Metabolism: Sufentanil is metabolized in the liver and the intestines; 80% of the 
administered dosage is excreted in 24 hours.  The end products of sufentanil are inactive.   
 
Elimination: The elimination half-life of sufentanil is 148 minutes. Sufentanil is excreted 
in the urine and bile.   
 
3.6.4 DOSAGE AND DIRECTIONS FOR USE 
 
The following dosages and directions are discussed according to the SASA sedation 
guidelines (2010:14).   
• The intranasal dosage of sufentanil for procedural sedation is 1µg/kg.  With this 
dosage the time to peak effect is 20 minutes and the duration of action is >60 
minutes.   
• When using sufentanil as an intravenous bolus the dosage is 0.02µg/kg.  
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• Sufentanil can also be used as a continues intravenous infusion.  The dosage ranges 
between 0.2 – 0.4µg/kg/hr.   
• The dosage of sufentanil should be individualized.  Factors to be considered in 
determining the dosage are age, body mass, physical status, underlying pathological 
condition, and the use of other medicines.   
 
3.6.5 SIDE EFFECTS AND SPECIAL PRECAUTIONS 
 
• Nausea and vomiting are side effects that are encountered regularly with opioid use 
often depending on the dosage given.   
• Pruritus and urinary retention have also been reported.   
• Bronchospasm, cough and hiccups are respiratory side effects that can occur.   
• Opioids can also cause chest wall rigidity, severe enough to prevent adequate 
ventilation . This is centrally mediated, and mostly seen after a large drug bolus.  It 
can be treated with muscle relaxants.   
 
Special precautions: Respiratory depression is dosage related and can be reversed by the 
specific narcotic antagonist, naloxone.  A repeated dosage of the antagonist may be 
necessary because the duration of respiratory depression may last longer than the duration 
of action of the opioid antagonist.  Marked respiratory depression accompanies profound 
analgesia.  It can persist into the post-operative period, and if sufentanil has been given 
intravenously it can recur.  Therefore patients should remain under appropriate observation.  
Resuscitation equipment and narcotic antagonists should be readily available.  Vital signs 
should be monitored routinely.   
 
3.6.6 DRUG INTERACTIONS 
 
Barbiturates, benzodiazepines, and other central nervous system depressants (e. g. alcohol) 
can have synergistic cardiovascular, respiratory and sedative effects with opioids.  When 
patients have received central nervous system depressants, the dosage of sufentanil required 
will be less than usual.   
 
The combination of opioids and monoamine oxidase inhibitors may result in respiratory 
arrest, hypertension or hypotension, coma and hyperpyrexia.  To prevent this, monoamine 
oxidase inhibitors should be discontinued two weeks prior to the administering of 
sufentanil.   
 
3.6.7 PERSONAL EXPERIENCE 
 
Sufentanil does not produce reliable sedation without significant respiratory depression.  
Therefore the author uses sufentanil in combination with propofol, midazolam and 
ketamine.  This combination of drugs also allows one to use small dosages of the opioid.   
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3.7 MEPYRAMINE MALEATE [ANTIHIST®] 
 
The discussion of mepyramine maleate is based on the approved package insert (Annexure 
P).   
 
3.7.1 CHEMICAL STRUCTURE 
 
 Mepyramine acts as an H1 receptor-antagonist with anti-allergy properties.  It is presented 
in 2ml brown glass ampoules.  Each millilitre contains 25mg mepyramine maleate.  The 
chemical group of mepyramine is an ethylenediamine (Reynolds 1993:926).   
 
The antihistamines have become useful agents for sedation and analgesia. They produce 
drowsiness, potentiate the sedative effects of the BZD, have anti-allergic properties, and 
prevent nausea and vomiting. Care must be taken in the elderly as the drugs may cause 
extra pyramidal symptoms. 
 
3.7.2 PHARMACODYNAMICS 
 
Mepyramine maleate can have the following effects: 
• It can cause ventricular arrhythmias, and in high dosages bradycardia followed by 
tachycardia.   
• In the respiratory system antihistamines show some anticholinergic activity, and this 
decreases secretions in the lung and sinuses, and thereby inhibit drainage and 
promote stasis.   
• In the central nervous system sedation is a side-effect of some antihistamines.  
Some patients may show central nervous system stimulation, specifically in 
children.   
• Secondary to antimuscarinic effects, patients can have a dry mouth.   
• Urinary retention can occur, also secondary to antimuscarinic effects.   
• The above side-effects are rarely seen with the low dosages we use for sedative 
purposes. 
 
Mechanism of action: Mepyramine acts as a competitive antagonist to histamine at the H1 
receptors.  The antigen-antibody reaction or other histamine-liberating stimulus is 
unaltered, but the histamine is prevented from acting on the effector organ (Meyers, Jawetz 
& Goldfien 1972:177).   
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3.7.3 PHARMACOKINETICS 
 
Absorption: The antihistamines are well absorbed after oral administration.  After oral 
administration onset of action is between 10 to 30 minutes.  In this study the mepyramine 
was used parentally, which bypasses first pass metabolism.  
 
Metabolism: Antihistamines are metabolized in the liver and kidney. 
 
Elimination: Antihistamines are excreted by the kidneys.   
 
3.7.4 DOSAGE AND DIRECTIONS FOR USE 
 
The different antihistamines have different dosages.  The newer antihistamines have longer 
dosage intervals.  In this study mepyramine was used intravenously in very small total 
dosages of less than 5mg.  Mepyramine maleate 1mg was added to the sedation mixture 
that was used in the infusion pump. In adult patients the dosage for use as an antihistamine 
in case of treatment or prevention of an allergic reaction is 25 to 50mg intramuscularly or 
intravenously. 
 
3.7.5 SIDE EFFECTS AND SPECIAL PRECAUTIONS 
 
According to Reynolds (1993:926-927) the following side-effects can occur: 
• Mepyramine exhibits central nervous system activity.  The most common side-
effect is sedation, ranging from mild drowsiness to deep sleep.  When practising 
sedation, it is this side-effect that we use to our advantage.   
• Other side-effects can include gastro-intestinal disturbances such as nausea, 
vomiting, diarrhoea or constipation and epigastric pain when used orally.   
• Headache, tinnitus, nightmares, dryness of the mouth and tightness in the chest may 
occur.   
• Paradoxically, you can get central nervous system stimulation, especially in 
children.   
• Hypersensitivity reactions may also occur.   
• Very rarely blood disorders have been reported.   
• Because of antimuscarinic properties, it should be used with caution in patients with 
closed-angle glaucoma, urinary retention, prostatic hypertrophy, and pyloro-
duodenal obstruction.   
• Elderly patients and those on antidepressants may get extra pyramidal symptoms 
and signs when antihistamines are used.   
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3.7.6 DRUG INTERACTIONS  
 
Antihistamines may enhance the sedative effects of central nervous system depressants like 
alcohol, barbiturates, hypnotics, opioid analgesics, anxiolytic sedatives, and neuroleptics.  
MAOIs may enhance the antimuscarinic effects of antihistamines.  Antihistamines have an 
additive antimuscarinic action if used with other antimuscarinic drugs, such as atropine and 
tricyclic antidepressants.   
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CHAPTER FOUR 
 
RESEARCH DESIGN AND METHODOLOGY 
 
 The previous discussion shows the obvious need for research on combinations of drugs for 
intravenous sedation in children to be done.   
 
4.1 PATIENT SELECTION 
 
Two hundred and two children who were healthy and under 10 years of age, and who 
needed dental treatment under sedation, were selected for this study. Two children were 
excluded because the intravenous cannula could not be placed in one child, and in the other 
child the sedation was stopped because the child was unmanageable. These two patients 
accounts for the 1% failure rate in this study. The remaining 200 patients were included in 
the data of this study.   
 
Sedation and dental treatment took place in a fully equipped dental surgery, meeting all the 
criteria for sedation outside the operating theatre, with all back-up systems in place in case 
rescue was needed.   
 
The dentists selected the patients who needed sedation for the procedure.  Two hundred 
children, male and female, were recruited for the study that lasted 2 years.  Only ASA I and 
ASA II patients (healthy patients) qualified for selection for sedation outside the operating 
room.  Patients with short term illnesses, especially upper respiratory tract infections were 
postponed for at least 4 weeks.   
 
4.2 INSTRUCTIONS TO PATIENTS 
 
• All patients received verbal as well as written instructions, and information on the 
dental and sedation procedure.   
• They were also informed about the research project.   
• The ethical statement (Annexure B) as well as a consent form (Annexure A) was 
signed by the parent or legal guardian.   
• A medical history questionnaire was given to the parent to complete before any pre-
medication was given.   
• All children were nil per mouth for at least 4 hours before the procedure.  If they 
had anything to eat or drink within 4 hours of the procedure, the operation was 
cancelled.   
• Transport was available to take the children home when they were ready to go after 
the procedure.   
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• A responsible adult, preferably the parent or legal guardian, accompanied the child 
home.   
• Full post-operative instructions, were given verbally as well as written information 
(Annexure C).  
• The parents were informed about the recovery process, the time it would take for 
the drugs to wear off, and the supervision needed once they were home.   
• Possible side effects of the drugs used, like nausea and vomiting, disorientation, 
sleepiness, double vision, amnesia, as well the numbness around the mouth because 
of the local anaesthetic were discussed.   
• Contact telephone numbers of both the dentist and sedation practitioner were given 
to the parents in case they wanted to discuss or report anything.   
 
4.3 PRE-SEDATION MEDICATION 
 
• All children were given an Emla local anaesthetic patch to put over a suitable vein 
on the hand or in the cubital fossa 2 hours before the procedure.  The Emla patch 
contains a mixture of lignocaine and prilocaine, which numb the skin for painless 
cannulation of a vein.  This we use to minimize the trauma that can result from 
cannulation.  Instructions were given to the parents on how to use the patch 
correctly as this was quite important to make the intravenous cannulation a painless 
procedure.   
• All children had to be at the surgery 30 minutes before the procedure.  Here they 
received oral midazolam, a sedative, for pre-sedation medication.  
• It was ensured that the children fasted according to the guidelines.  
• Children younger than 6 years received 3.75mg (half a tablet) of midazolam orally.  
Children older than 6 years received 7.5mg of midazolam orally.  The children were 
given the tablet to swallow with 10 – 15ml of clear water.  If they were unable to 
swallow the tablet, they were then instructed to chew the tablet and then swallow it 
with water.   In the few children who refused to take the tablet, the parenteral 
solution was used.  The parenteral solution was given at a dosage of 0.5mg/kg to a 
maximum of 5mg. It was mixed with paracetamol or ponstan syrup to mask the 
taste of the midazolam.  Children under 2 years of age did not receive any 
premedication.  If the child was not co-operative after the midazolam pre-
medication, ketamine 2mg/kg was added orally.  The parenteral solution was used.  
This was mixed with paracetamol or ponstan to mask the taste of the ketamine.   
• The drug was administered in the dentist’s room and not at home.  Patients react 
very differently to midazolam, and their level of sedation varies individually.  
Therefore the pre-medication must be administered under supervision of the 
sedation practitioner.   
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• An important aspect of a successful sedation technique always is behaviour 
management. This can be challenging in a child. You have to make contact with 
your patient on their level, and not be intimidating.  Explaining to the children and 
parents what you were going to do, goes a long way in ensuring them that they are 
not going to be hurt.  It’s all about gaining their trust.   
 
• All patients were covered with a blanket to comfort them, as well as to keep them 
warm.   
 
4.4 BOLUS SEDATION PROCESS 
 
Boluses of drugs were used for shorter procedures such as extractions for orthodontic 
indications and small fillings.  These procedures were 15 – 30 minutes in duration.   
The drugs used were midazolam and ketofol.  Ketofol is made up of a mixture of ketamine 
and propofol.   
 
In this bolus sedation technique, the children received 0.5 mg of midazolam intravenously 
and 1ml of ketofol.  An additional dosage of 0.5mg midazolam and 1ml of ketofol was 
titrated to effect if necessary.  If the procedures lasted longer than 10 to 15 minutes, the 
ketofol dosage of 1ml was repeated when necessary.  Bolus sedation techniques for 
children for short procedures are often used in the sedation world and have become very 
popular.   
 
4.5 USING AN INFUSION PUMP 
 
Procedures lasting longer than 30 minutes were done with this technique using an infusion 
pump. It is well known that we have better control over drug administration as well as more 
predictable sedation levels when using infusion pumps.  The children also received a bolus 
of midazolam 0.5 – 1mg, glycopyrrolate 0.5ml (0.1mg) and before local infiltration of the 
local anaesthetic agent, ketamine 0.25mg/kg intravenously.  The infusion rate of drugs with 
the infusion pump was set according to their weight in mg/kg.  The following drugs were 
drawn up in a 20ml syringe which was administered through the infusion pump:   
• propofol 100mg (10ml),  
• mepyramine maleate 12.5mg (0.25ml),  
• ketamine 25mg (0.5ml), and  
• sufentanil 2.5µg (0.5ml).   
This mixture was made up to 12ml with sterile water.  Each ml of solution contained 
propofol 8.3mg, mepyramine maleate 1mg, ketamine 2mg and sufentanil 0.2µg.   
Of this mixture children received a bolus of 0.5mg/kg and then the pump was set between 
1-4 mg/kg/hr, where the propofol was used to calculate dosages.  In this study a multidrug 
infusion technique was used.  To be able to administer the multidrug mixture in one 
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infusion pump, all the different drugs were mixed together as described in the previous 
paragraph.  To be able to calculate dosages, only one drug in the syringe is used as a 
reference.  In this mixture the propofol was used as reference for calculating the dosages.   
 
4.6 MONITORING 
 
The children were monitored throughout the procedure with a Welch Allyn Propac LT® 
haemodynamic monitor, measuring pulse rate, oxygen saturation, blood pressure, 
respiratory rate, and a 3 lead ECG tracing.  The level of sedation (LOC) according to the 
Wilson scale (Annexure G), was also continuously monitored by the sedation practitioner 
who was present during the whole procedure.   
 
The ideal would be to use a Bispectral Index (BIS) monitor, which measures LOC in 
patients.  Unfortunately these monitors are very expensive and not readily available outside 
the hospital setting.  These monitors have not been validated for sedation. It is also difficult 
to place electrodes on the heads of children as this may make them very anxious.   
 
All patients were left to sleep undisturbed for 30 minutes after the procedure.  If their 
observations were back to normal after 30 minutes they were sent home with written and 
verbal instructions.  The Steward scale (Annexure F),  was used as an indication for 
discharge criteria.  BP, pulse rate, respiratory rate and saturation levels were monitored 
before induction and every 10 minutes during the procedure.  The last reading was done 
before the child was left in their parents care. The ECG was monitored continuously.  
 
4.7 FACILITIES FOR RESUSCITATION 
 
Resuscitation equipment was unpacked and ready to use with every procedure.  This 
included:  oxygen, ambubag, airways, endotraceal tubes, laryngeal masks, laryngoscope, 
suction catheter, defibrillator and emergency drugs as stated in all international guidelines .   
Drugs used as reversal agents for the opiates and midazolam, namely naloxone and 
flumazenil were readily available.  Facilities need to be available if an escalation in care 
occur.   
 
4.8 EVALUATION CRITERIA 
 
All patients were evaluated during sedation and surgery using the following criteria: 
1. Age. 
2. Gender. 
3. Medical  History. 
4. Weight. 
5. Reasons for Surgery. 
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6. Pre-sedation Medication Received. 
7. Ease of Cannulation. 
8. Comparison of Sedation and Surgery Time. 
9. Sedation Level according to the Wilson Sedation Scale. 
10. Observations. 
11. Steward Recovery Score. 
12. Surgeon Evaluation. 
13. Sedation Practitioner Evaluation. 
14. Parent Evaluation. 
 
All these different parameters were analyzed to evaluate the safety and efficacy of 
techniques used. Results are discussed in the following chapter.  
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CHAPTER FIVE 
 
RESEARCH FINDINGS AND ANALYSIS 
 
The research findings and analysis will be discussed and mainly presented in graphic 
format.   
 
5.1 AGE 
 
This study was done on children between the age groups of two to ten years of age.  The 
graph shows that the largest group of children were between four to eight years of age.  
There were six children included in the study who were two years old.  These children were 
evaluated before the procedure to ensure that their airways were suitable for a sedation 
procedure.  The average age in this study was 5.9 years and the median age was 6 years.   
 
Graph 5:1 
 
5.2 GENDER 
 
The gender ratio was almost 50:50 with 101 male patients and 99 female patients as shown 
in the graph below.   
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5.3 MEDICAL HISTORY 
 
For sedation outside an operating room, only ASA 1 and 11 patients should qualify 
according to all international guidelines on sedation.  This is a very important rule to adhere 
to, specifically when working with children.  This is supported by our local sedation 
guidelines for children.  The following graph shows interesting reading as to medical 
disease reported by parents or guardians on the medical history questionnaire:  
• Fourteen of the children were born as premature babies.  All international guidelines 
caution about the wisdom of doing those cases outside the operating room.  
• The one child who had cardiovascular disease had a one out of six heart murmur.  
She was six years old and was seen by a paediatric cardiologist.  She never had any 
invasive cardiac procedures and was not on any medication.  She could perform any 
physical activity according to her age, and was therefore classified as an ASA 2 
patient.   
• Seven of the children included in the study had asthma.  All of these children were 
on medication that controlled their symptoms.  On the day of the sedation, these 
children were well with no coughing or wheezing.  The sedation procedures in these 
children were all done without any respiratory adverse events, and no oxygen was 
used.   
• One of the children had kidney disease.  This child was born with one kidney.  
Kidney function was normal.   
• Eleven of the children included in the study were on medication for Attention 
Deficit Disorders (ADHD).  Only two of these children were difficult to sedate.  
These patients are sometimes difficult to work with, but being on methylphenidate 
hydrochloride or atomoxetine hydrochloride does not necessarily mean that they are 
difficult to sedate.   
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5.4 WEIGHT 
 
The weight chart is shown below.  None of the children were cancelled because of obesity, 
but children weighing less than 10kg were not included in this study.  The bottom 
horizontal line of the graph shows the weight in kilogram and the legend above each line 
shows how many children with the same weight were studied.  The first graph shows the 
weight distribution from 10 to 25kg and the second graph from 26 to 41kg.  The average 
weight was 23.055kg.  The median weight was 22kg.   
 
 
Graph 5.4.1 
 
 
Graphs 5.4.2 
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5.5 REASONS FOR SURGERY 
 
The indications for surgery and sedation are shown in the following graphs.   The children 
were evaluated according to their age; 2 – 4 years, 4 – 6 years, 7 – 8 years, and 9 – 10 
years, with the different procedures done shown.    
 The following legends were used as abbreviations for the type of procedures on the graphs: 
E- Extractions,  
F – Fillings,  
R- Rootcanal,  
FP – Fillings and pulpotomy’s,  
FE – Fillings and extractions,  
T – Tooth exposure and  
Fr – Frenectomy.   
 
In the age group 2 to 4 years which included 49 children, all the procedures were fillings, or 
fillings with extractions or pulpotomy’s.  Only 3 children had only extractions done.  Most 
of the children booked for sedation needed work on multiple teeth.  This is quite an 
interesting observation as it may indicate that more fillings are done in this age group to 
prevent children losing teeth.   
 
 
Graph 5.5.1 
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In the age group 5 to 6 six years there were 67 children.  Again in this group the procedures 
included extractions, fillings, and fillings with pulpotomy’s or extractions.  One child had a 
frenectomy done.  This procedure is ideally suited for sedation since the administering of 
the local anaesthetic agent can be quite painful.   
 
 
Graph 5.5.2 
 
In the age group 7 to 8 years there were 59 children.  In this group the procedures were 
varied.  Extractions, fillings, fillings and extractions and frenectomy’s were done.  Also 
included in this group were 3 root canal treatments on the number 6 teeth (first permanent 
tooth to erupt).  One child had a tooth exposure.   
 
 
Graph 5.5.3 
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The group 9 to 10 years only included 22 children.  The smaller number of children is an 
indication that the older the children are, the better they co-operate for dental treatment.  
The indications for extractions included orthodontic extractions in this group.  Only one 
child had a root canal treatment.   
 
 
Graph 5.5.4 
 
When we look at the overall picture in graph 5.5.5 we see that:  
• 37.5% of the sedations were done for fillings or fillings with pulpotomy’s 
• 58.5% of the procedures were done for extractions or extractions and fillings 
• 1.5% frenectomy’s  
• 2% root canal treatments  
• 0.5% tooth exposure  
 
 
Graph 5.5.5 
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5.6 PRE-SEDATION MEDICATION RECEIVED 
 
Pre-sedation medication was given to all the children.  Although this is a controversial topic 
we felt it best that children be calm and relaxed when they enter the dental surgery.  Many 
children had traumatic experiences in the past therefore sedative drugs can be very helpful 
in these cases; amnesia is useful.  We understand that there is no ideal sedative drug yet 
available but overall midazolam does offer benefits.   
The following dosing schedule was used: 
• Children under the age of six years received midazolam 3.75mg.  This was given as 
half a 7.5mg tablet (the normal size) that could either be swallowed or chewed.  A 
small amount of water was given to the children to swallow the tablets.   
• Children older than six years of age received a 7.5mg tablet of midazolam.   
• If the children were unable to swallow the tablet, they were given the same dosage 
of the aqueous solution mixed with 3ml (30mg) of mefenamic acid to hide the bitter 
taste.  
•  In one case midazolam was not used, because the child had a previous exposure to 
midazolam with a paradoxical reaction, where he became severely hyperactive.  
This child only received ketamine per os as pre-sedation medication.   
• Sixteen children received a second dosage of pre-sedation medication, because they 
were un-cooperative with the midazolam pre-medication alone.  These children 
received  midazolam liquid solution and ketamine mixed together with mefenamic 
acid or paracetamol syrup.  The ketamine was administered at a dosage of 2mg/kg.  
With this regime only two children were cancelled, because the intravenous line 
could not be introduced.   
The pre-sedation medications administered, are shown in the following graphs.  
 The first graph (5.6.1) shows the total amounts of midazolam that was used.  Sixteen of the 
children required a second dosage of pre-medication, and the total dosages of midazolam 
are displayed.  
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The second graph (5.6.2) shows the oral ketamine that was given together with midazolam 
as a second dosage of pre-sedation medication for the unco-operative children.  One of 
these children received only ketamine because of a reciprocal reaction to midazolam.   
 
 
Graph 5.6.2 
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place an EMLA patch over a vein to anaesthetise the skin.   
The quality of cannulation was evaluated in every patient.   
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Easy 0  
Difficult 1  
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      Table 1 
 
The cannulation was evaluated as easy when the child was calm and co-operative, and the 
cannula was placed within 2 minutes.  Difficult cannulation was noted when the child was 
anxious and apprehensive, and even crying, and the cannulation took more than 5 minutes.   
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Looking at graph 5.7, the cannulation process was rated as follows:  
• 80.7% were easy,  
• 6.9% were difficult,  
• 11.4% of children needed more than one puncture, and  
• 1% was cancelled because the intravenous line could not be placed.   
Egelhoff et al. in 1997 [8] concluded that they had a sedation failure rate of one percent, 
which is the same as the researcher found in this study.   
 
 
Graph 5.7 
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Graph 5.8.1 
 
Graph 5.8.2 
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Graph 5.8.4 
 
Graph 5.8.5 
 
Graph 5.8.6 
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Graph 5.8.7 
 
Graph 5.8.8 
 
Graph 5.8.9 
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5.8.2 DURATION OF SEDATION 
 
Graph 5.8.10 shows that the sedation times in minutes lasted from as short as 10 minutes to 
as long as almost two hours.  Some of the children tended to get restless if the sedation was 
very long, and this sometimes made the sedation and the procedure more difficult.  Because 
of this, dentists are advised not to work for more than an hour per case.  If there is a lot of 
work that needs to be done, the parents are also informed before sedation that we might 
need to finish the work in a second sedation session.  If you discuss this possibility before 
surgery with the parents, they will accept this possibility without hesitation.   
 
Graph 5.8.10 
 
5.8.3 DURATION OF SURGERY 
 
Graph 5.8.11 shows the length of the procedures. It can be seen that most operations lasted 
less than 60 minutes which is indicative of the excellent planning of dental sedation 
procedures.  In the researcher’s practice 30 minutes is added for time booked for each 
patient.  This covers the time from the start of the sedation until discharge criteria is met.   
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5.8.4 RECOVERY TIME 
 
Graph 5.8.12 shows the recovery times of all the patients.  Most of the children were 
opening their eyes or moving their limbs after 5 to 10 minutes.  The children were then left 
in the care of their parents and the recovery staff until they were discharged to go home.  
One child only recovered after 60 minutes.  This child was very difficult to sedate and had 
excessive movement during the sedation, which required higher dosages of the infusion 
mixture, which could explain the long recovery time.  This is typical of deeper sedation 
levels; deeper levels will result in longer recovery times.   
 
Graph 5.8.12 
 
5.8.5 CLARIFYING PIVOT TABLE 
 
A clarifying table (p.51), is included that shows the analyzed data concerning the recovery 
time and types of procedure.  The type of procedure has no statistical influence on the time 
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recovery time.  No statistical significance was shown.   
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REASON 
      
           MF                                                         Values E F S SE SP T W Total 
                 F           Count of Diff 'Sedtn - Dur Srgry'  21 1 28 36 9   4 99 
 
Average of Diff 'Sedtn - Dur Srgry'  6.90 5.00 7.50 7.31 8.89   10.00 7.51 
 
StdDev of Diff 'Sedtn - Dur Srgry'  4.323 #DIV/0! 2.887 2.867 2.205   0.000 3.167 
 
Min of Diff 'Sedtn - Dur Srgry'  0 5 5 3 5   10 0 
 
Max of Diff 'Sedtn - Dur Srgry'  20 5 15 15 10   10 20 
          
                M Count of Diff 'Sedtn - Dur Srgry'  12 2 29 48 9 1   101 
 
Average of Diff 'Sedtn - Dur Srgry'  8.33 5.00 9.14 6.98 10.00 5.00   7.97 
 
StdDev of Diff 'Sedtn - Dur Srgry'  7.177 0.000 10.443 2.471 6.124 #DIV/0!   6.602 
 
Min of Diff 'Sedtn - Dur Srgry'  5 5 0 5 5 5   0 
 
Max of Diff 'Sedtn - Dur Srgry'  30 5 60 10 25 5   60 
          
             Total Count of Diff 'Sedtn - Dur Srgry'  33 3 57 84 18 1 4 200 
             Total Average of Diff 'Sedtn - Dur Srgry'  7.42 5.00 8.33 7.12 9.44 5.00 10.00 7.74 
             Total StdDev of Diff 'Sedtn - Dur Srgry'  5.466 0.000 7.696 2.636 4.501 #DIV/0! 0.000 5.186 
             Total Min of Diff 'Sedtn - Dur Srgry'  0 5 0 3 5 5 10 0 
             Total Max of Diff 'Sedtn - Dur Srgry'  30 5 60 15 25 5 10 60 
                                                   Table 2 
 
If one looks at the recovery times then it is clear that the majority of children recovered 
within 5 – 10 minutes. This shows that the sedation techniques were well planned and that 
deep sedation was not done. Most important is that children can be safely done outside the 
operating room by experienced sedation practitioners. 
 
5.9 SEDATION LEVEL 
 
The sedation levels of the children were evaluated according to the Wilson Sedation Scale 
which is universally accepted for the evaluation of the level of consciousness (LOC) 
(Annexure G, p. 103):   
 
1 Fully awake and oriented 
2 Drowsy 
3 Eyes closed but rousable to verbal command 
4 Eyes closed but rousable to mild physical stimulation (earlobe tug) 
5 Eyes closed, not rousable to mild physical stimulation 
 
 A level 5 on the Wilson scale equals deep sedation, which is not safe and not allowed 
outside the operating room. The level of sedation used for this study, varied between a level 
3 and 4 on the Wilson scale (which is moderate sedation and analgesia), depending on the 
co-operation of the children.   
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Graph 5.9 shows the following:  
• 62.5% of the children were done according to a Wilson sedation scale level of 3, 
• 32.5% were on a sedation level of 4.   
These levels are considered as safe by all international guidelines when children are 
sedated.   
 
 
Graph 5.9 
 
5.10 OBSERVATIONS 
 
In the following discussion the patients’ observations will be discussed under the following 
headings:  
• Pulse rate,  
• Respiratory rate, 
• Oxygen saturation levels and  
• Blood pressure.  
The observations were recorded every 10 minutes.   
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The following graph shows the number of subjects that were studied sequentially at each 
measurement time.  The procedures ranged from 10 minutes to 110 minutes.  On this graph 
the time up to 90 minutes is shown.   
 
 
Graph 5.10.1 
 
Graph 5.10.1 shows something very interesting in terms of procedure and sedation times, 
and numbers of children done under sedation e.g. 160 children (80%) were done in 30 
minutes; 20 children (10%) were done in 80 minutes. 
 
This study shows the trend of current sedation practice as the majority of sedation 
procedures are short in duration. This obviously will add to the safety of paediatric sedation 
practice. 
 
5.10.1 PULSE RATE: 
 
This study included patients from 2 to 10 years of age. The normal values for pulse rates in 
children not receiving sedation differ in each age group and are as follows (Heese 1992:99) 
• 2 – 3 years: 100 – 180 (130) beats per minute 
• 4 – 5 years: 60 – 150 (100) beats per minute 
• 6 – 8 years: 60 – 130 (100) beats per minute 
• 9 – 10 years: 50 – 110 (80) beats per minute 
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According to the Spearman Correlation report (Annexure J, p. 106) this research study 
confirms the following: 
• There is an inverse correlation between the age, weight and pulse rate of the 
children.  The older the children (also the heavier they are), the slower their pulse 
rates.  This is a confounding measurement with a P value of 0.0000.  This is to be 
expected in older children.   
• There is an inverse relationship between the pulse rate at the start of the procedure 
and the pulse rate that was measured at the 10 minute interval (P= 0.0023).   
• The maximum pulse rate and the pulse difference at 10 minutes were positively 
related (P=0.0009).  There was an increase in pulse rates.   
• The maximum – minimum pulse rate correlates closely to the maximum – minimum 
respiratory rate (P=0.0000).  This is to be expected when the paediatric sedation 
technique used meets all the requirements of safe paediatric sedation.   
 
Graph 5.10.1.1 shows the median and average pulse rate over time.  The values lie between 
96 and 114 beats per minute.  This is well within the ranges of the pulse rates in any age 
group as shown above.  This is consistent with what we see in paediatric sedation practice.   
 
 
Graph 5.10.1.1 
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Graph 5.10.1.2 shows the standard deviation of pulse rate over time.  The longer the 
procedure lasted the smaller the deviation in pulse rate.  The pulse rate deviation was the 
highest in the first 40 minutes.  The use of glycopyrrolate as part of the induction can 
explain this increase in pulse rates.  Anxiousness in the patients also contributes to the 
increase in pulse rates. 
 
 
Graph 5.10.1.2 
 
Graph 5.10.1.3 shows the average pulse rate on the horizontal axes and the difference 
(maximum minus minimum) in pulse rate on the vertical axes. The values are fairly 
concentrated in the area between 71 to 165 on the horizontal axes and 0 to 77 on the 
vertical axes. This is to be expected with safe paediatric sedation. 
 
Graph 5.10.1.3 
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Graph 5.10.1.4 shows the average pulse readings from the start and 10 minute reading 
compared to the average pulse rate over the full range of time.  Most of the values are 
above the diagonal line on the graph, meaning the average pulse rate was higher than the 
pulse rate at the beginning of the procedure.  This is to be expected as stimulation will add 
to an increase in pulse rate. This also shows that procedures are done under sedation and 
not general anaesthesia. 
 
Graph 5.10.1.4 
 
Graph 5.10.1.5 shows the difference in pulse rate (pulse rate at 10 minute reading – the 
pulse rate in the beginning) compared to the range of the pulse rate. The diagonal trend of 
the pulse rate on the right hand side of the vertical line is an indication that the pulse rate 
increased at the beginning of the procedure.  This increase in pulse rate is due to the use of 
glycopyrrolate at the beginning of the procedure. Anxiousness in the patients can also 
contribute to this finding. Trying to find an adequate level of sedation e.g. not too light 
sedation versus not too deep sedation may contribute to this finding.   
 
Graph 5. 10.1.5 
60.00
70.00
80.00
90.00
100.00
110.00
120.00
130.00
140.00
150.00
160.00
170.00
180.00
60 70 80 90 100 110 120 130 140 150 160 170 180
Av
er
g 
fu
ll 
Ra
ng
e 
Average Start & Pulse10 
Average (Start & Pulse10) vs Averg full Range 
0
10
20
30
40
50
60
70
80
90
-40 -30 -20 -10 0 10 20 30 40 50 60
Av
er
g 
fu
ll 
Ra
ng
e 
Average Start & Pulse10 
Diff (P10-Start) & Range of Pulse 
 
 
 
 
 58 
Graph 5.10.1.6 shows the average pulse rate on the horizontal axes and the difference in 
pulse rate (pulse rate at 10 minute reading – pulse rate at the start) on the vertical axes.  
This graph shows that as the pulse rate increase during sedation on the horizontal axes, the 
difference in the pulse rate on the vertical axes also increases.  This is to be expected 
because drugs are administered to children.   
 
 
Graph 5.10.1.6 
 
A total of 5% of all the children had a tachycardia of between 160 and 180 beats per 
minute, and 0.5% (one patient) had a pulse rate of more than 180 beats per minute. The 
high pulse rates could be caused by the antisialogue administered before induction of 
sedation. Anxiety could also contribute to this finding.   
 
There was an overall increase in the pulse rates after induction at the beginning of the 
procedures as explained above.   
 
The one patient with the pulse rate of more than 180 per minute had a history of a cleft 
palate that was surgically repaired.  The mother gave a history that she does not tolerate any 
foreign objects in her mouth, which was very obvious when we inserted the bite block.  
“Oral defensive” is a well known entity in children with a cleft palate, although it is not 
well documented.  Her pulse rate was between 158 and 182 throughout the procedure.  This 
can be explained because the child was done under sedation and not general anaesthesia.   
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5.10.2 RESPIRATORY RATE: 
 
• The Spearman Correlations Report (Annexure J, p 106 ), show an inverse 
correlation between the respiratory rate and the age of the patients (P=0.0081).   
• Both the pulse rate at the start of the procedure and the average pulse rate show a 
positive relationship with the respiratory rate (P=0.0000).   
• This indicates that the faster the respiratory rate of the patient, the faster the pulse 
rate was.  This is a normal expected physiological finding.   
 
Graph 5.10.2.1 shows a decrease in the respiratory rate over time.  The longer the 
procedure lasted the slower the respiratory rate became.  One could argue that there is not 
much significance in reporting this; however when using opiates in children a decrease in 
respiratory rate could be an indication of respiratory depression.   
 
 
Graph 5.10.2.1 
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Graph 5.10.2.2 shows the maximum and minimum respiration rates.  The maximum 
respiratory rate and this graph are indicative of tachypnea.  This correlates with the 
tachycardia seen with the one patient who had a cleft palate repair.  This increase in 
respiratory rates may be due to anxiousness, and yet not finding the desired sedation level.  
However it shows the sensitiveness of the sedation practitioner in not giving over dosages 
of drugs.   
 
 
Graph 5.10.2.2 
 
Graph 5.10.2.3 shows the respiration rate slowing down the longer the procedure lasted.  
Most of the painful stimuli are in the beginning of the procedure with the administration of 
the local anaesthetic and drilling.  Once the patients were sedated their respiratory rate and 
pulse rate decreased.  This is to be expected when we reach a desired level of sedation and 
indicative of a safe sedation technique.   
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Graph 5.10.2.4 shows the average respiratory rate on the horizontal axes and the difference 
between the maximum and minimum respiratory rate on the vertical axes. 
 
 
Graph 5.10.2.4 
 
• The respiration rate varied from patient to patient.  Most of the patients showed a 
slight increase in respiration rate after induction, which settled quickly with sedative 
drugs taking an effect.   
• Two of the children started off with tachypnoea.  Both of these children were 
extremely anxious.  Their respiratory rates settled soon after induction, once the 
children were sedated.  
• Tachypnoea in children before sedation is a very important observation and care 
should be taken that the children do not suffer from a respiratory tract infection.  
• There was no respiratory depression noted, which can be caused by midazolam, 
propofol or sufentanil. This is a very important observation when doing sedation in 
children as it points to safe sedation practice. The absence of respiratory depression 
is probably due to the extremely low dosages that were used.   
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5.10.3 OXYGEN SATURATION: 
 
Graph 5.10.3 shows the average oxygen saturation over the full range against the difference 
(maximum – minimum) in oxygen saturation.  The greatest number of patients on the graph 
lies above 95% oxygen saturation with a difference of less than 5%.  Monitoring the 
oxygen saturation in children is very important because respiratory complications are the 
most common and life threatening.   
 
One child started with an oxygen saturation reading of 85%.  This child was very anxious 
and moving about which made an accurate reading impossible.  As soon as the child was 
sedated and he settled down, the oxygen saturation improved.  
  
The respiratory complication rate in this study was 7%. Of these only 3% or six patients 
needed oxygen administration.  In all the cases of desaturation it was caused by obstruction 
of the airway by the dentist while working or too much water on the drill.  In all the cases 
the problem was treated and the oxygen saturation restored within seconds with no serious 
consequences.   
 
 
Graph 5.10.3 
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5.10.4 BLOOD PRESSURE 
 
In children the blood pressure is dependent on the pulse rate.  Changes and abnormal blood 
pressure readings will be discussed in the section of adverse events (p74).   
 
There is no clarity on the evaluation of blood pressures in small children.  There are 
arguments that when you inflate the cuff this may change your level of sedation.  One 
expects normal blood pressures in ASA 1 and 2 children.   
 
The following three scatter graphs show the average blood pressure readings for systolic, 
diastolic and mean blood pressure readings.  The blood pressure was monitored every 10 
minutes during the sedation.  These graphs do not show any significant trends in the blood 
pressure measurements.  A drop in blood pressure is rarely seen and not really significant in 
the ASA 1 and 11 patients.   
 
 
Graph 5.10.4.1 
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Graph 5.10.4.2 
 
 
Graph 5.10.4.3 
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5.11 STEWARD RECOVERY SCALE 
 
There are quite a variety of recovery scales available to assess recovery which is all 
subjective. The Steward Recovery scale (Steward 1975) is widely used to evaluate patients 
before being discharged to go home.  The decision on when to discharge a child is very 
important as adverse events can happen even at home. All children should be fully 
recovered before they can be sent home.  That implies that they must have a Steward score 
of six.  The Steward score is calculated as follows: 
  PARAMETER                          FINDING   POINTS 
  Consciousness   Awake 2 
     Rousable and responding to stimuli 1 
     Not responding to stimuli 0 
  Airway   Coughing on command or crying 2 
   Maintaining good airway and breathing easily  1 
   Airway requires maintenance 0 
  Movement   Moving limbs purposefully 2 
   Non-purposeful movements 1 
   Not moving 0 
   
Table 3: 
Interpretation:   
 ~ Minimum score 0:  fully anaesthetized, not ready to be discharged 
 ~ Maximum score 6:  fully recovered 
 
Graph 5.11 below shows that all the children in the study scored a 6 on the Wilson recovery 
scale meaning they were fit to be discharged.  Despite this fact, one parent reported in the 
second questionnaire that the child was sleeping and difficult to rouse on their journey 
home.  This just accentuated the importance of discharge criteria but also the value of 
clinical monitoring after sedation. This also adds to our concerns about drug administration 
to children. Non stimulation may have contributed to slow recovery in the child mentioned.  
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5.12 SURGEON EVALUATION OF EFFICACY OF SEDATION IN 
CHILDREN 
 
The operator or surgeon is a valuable component of sedation practice. In this study the 
operator was asked to evaluate the quality of sedation.  A table with a scoring system was 
used (see below) to ensure that the different operators use the same evaluation technique.  
The children were evaluated according to two parameters, namely movement and 
vocalising.  
 
Vocalising was evaluated as a  
• score of 1 when the patient was talking. 
• 2 if the patient was complaining (moaning) with administration of the local 
anaesthetic. 
• 3 if the patient was screaming with local anaesthetic administration or other 
stimuli.  
• 4 in case of uncontrollable screaming and procedure were cancelled.  
 
  The following table was used during sedation: (researcher and supervisor) 
 
 
 
Movement 
0 
No 
movement 
1 
Slight 
movement, not 
interfering with 
procedure 
2 
Moderate 
movement, not 
interfering with 
procedure 
3 
Major 
movement, 
procedure done 
with difficulty 
4 
Uncontrollable 
movement, 
procedure  
not possible 
 
 
Vocalising 
0 
No 
vocalising 
1 
Slight 
vocalising, 
talking 
2 
Moderate 
vocalising, with 
local 
administration, 
not disturbing 
3 
Major vocalising, 
screaming 
4 
Uncontrollable 
vocalising, 
screaming 
throughout 
procedure.  
(not because of 
pain) 
Table 4 
 
The results of the evaluations of the two above parameters are listed below in graph 5.12.1.  
Note that none of the patients had a score of 4 which means that it is impossible to 
complete the procedure.  It is debatable whether a child scoring 4 in either category will be 
suited for a procedure under sedation.  It may only be possible with deep sedation.  The 
quality of work performed when the child is moving that much is questionable.  Part of the 
consent form for sedation states that sedation is not a guarantee that the work will be done.  
In the opinion of the sedation practitioner it is acceptable to cancel sedation in case of 
excessive movement or vocalising. It is in fact advisable to inform parents before the 
operation of this possibility.  It is no shame in abandoning a procedure and proceed to 
general anaesthesia. 
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Eighty percent (80%) of the children scored a 0 or 1 on the movement scale.  This implies 
that the children were co-operative and easy to work on; 91.5% of the children scored a 0 
or 1 on the vocalising scale which means that they were quiet, and not talking excessively.  
The procedure was thus not difficult to complete.   
 
Seven percent (7%) of the children had a score of three when movement was evaluated, and 
1.5% scored a three on vocalising.  These sedations were marked as difficult.  Despite the 
fact that these sedations were difficult to do, all the work was still completed.  The decision 
whether these children will be scheduled for a future sedation lies with the operator and 
sedation practitioner together.  It must also be remembered that a difficult sedation may not 
exclude the possibility of sedation in future; this must also be discussed with the parents.  
This shows the safety and efficacy of the technique used. 
 
 
Graph 5.12.1 
 
 
Graph 5.12.2  
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5.13 SEDATION PRACTITIONER EVALUATION OF SAFETY AND 
EFFICACY 
 
The evaluations from the sedation practitioner’s point of view will be discussed in the 
following section under the following headings: general, post-operative recovery, safety 
and efficacy.  This should give a valuable contribution as to how difficult or easy sedation 
was.  It will also give an indication as to safety and efficacy of the sedation technique.   
 
5.13.1. General 
 
From the sedation practitioner’s view, the sedations were evaluated on a three- point scale 
as: 
• good,  
• fair, and  
• difficult.  
The results can be seen in the following graph 5.13.1  
 
Graph 5.13.1 
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with little or no movement, and they were able to maintain their airway with little or no 
interference. The surgeon was never requested to stop the operation in this group. 
• Fair 
The sedation was rated as fair when there was more movement or airway management 
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children is not always easy and that expertise is necessary to manage children, especially 
protection of the airway. 
• Difficult 
Sedation was classified as difficult when the children were moving excessively, or airway 
management was needed throughout the procedure.  In these cases the work was completed 
with difficulty.  This group made out 9% of the study group.  This group that were found to 
be difficult to sedate correlates with the findings of the operator/dentist where the results of 
the vocalizing and movement scores were 8.5% scored as a value of 3, which indicated 
severe movement or vocalizing.  This again shows that even with experienced sedation 
practitioners involved in paediatric sedation outcome cannot be easily predicted.  Maybe 
one can say not all children qualify for paediatric sedation.  Children must be evaluated 
before sedation as to suitability of sedation.   
 
This study also included a questionnaire that the parents completed.  One of the questions 
asked was about behavior characteristics of the child.  This was asked to try to find a 
common trait that might predict a difficult sedation.  With the results that were received, no 
common denominator could be found to predict a difficult sedation.  Craig and Skelly [6] 
state the following: “Despite a number of recent studies it has not been possible to identify 
any factor or group of factors which may be used to predict the likelihood of success.”   
 
This confirms the researcher’s findings that there is no factor that could be found to predict 
a difficult sedation in ASA 1 and 2 children.   
 
5.13.2. Post Operative Recovery and Side-effects 
 
The success of the sedations procedures also depends on the post-operative recovery 
characteristics of the children.  We do not want to see children are not controllable after 
sedation or with a high incidence of side effects.  The most common side effects and 
complications are listed in order of prevalence, and were evaluated in every child.  
Although two patients complained of pain, only one was objectively in pain.  Some 
children confuse the tingling feeling of the local anaesthetic with pain.  The following are 
the post-operative side effects that were seen and are displayed in graph 5.13.2:   
 
Confusion 12% Restlessness 1% 
Crying 10.5% Pain 1% 
Drowsy 10.5% Hallucinations 1% 
Double vision  7.5% Headache 0.5% 
Prolonged sedation 6% Vomiting 0.5% 
Nausea 2%   
 
 
 
 
 
 
 70 
• Confusion, crying, drowsiness and double vision were the most common side-
effects that were noted.   
• The incidence of nausea and vomiting is very low if compared to general 
anaesthesia. The side effects mentioned are commonly seen after paediatric sedation 
using intravenous drugs.   
• The incidence of hallucinations is only 1%, even with the use of ketamine.  None of 
the children had bad or scary hallucinations.  This low incidence of hallucinations is 
probably due to the low dosages of ketamine used.  
• Restlessness, pain and headache were seen very seldom.  
 
 
Graph 5.13.2 
 
This research study shows that postoperative side effects are inevitable.  Children are 
usually anxious, find themselves in a threatening environment, and receive drugs.  All 
contribute to the incidence of side effects.  Despite these side effects mentioned the 
majority of children recover without any side effects.   
 
5.13.3. Safety 
 
From the sedation practitioner’s point of view, the sedations (drug administration) were 
also evaluated for safety and efficacy.  
The safety was evaluated according to the following criteria:  
• Level of consciousness,  
• Maintenance of the airway,  
• Respiratory (breathing) pattern and  
• Haemodynamic adverse events.  
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 The following table was used to score the patients:   
 
Scoring table to evaluate safety: 
 
 
 
Consciousness 
0 
 
Eyes open or 
closed, responds to 
verbal stimulation 
-1 
 
Ptosis, 
responds to 
physical 
stimulation 
-2 
 
Eyes closed, 
only response 
reflex to 
stimulation 
-3 
 
Eyes closed, 
no response to 
physical 
stimulation 
 
 
 
Airway 
0 
 
Controlled 
adequately by 
patient….breathing 
spontaneously, no 
accessory muscles 
involved 
-1 
 
Minimal 
interference 
needed to 
maintain the 
airway e.g. 
extend neck 
-2 
 
Airway 
management 
e.g. chin lift 
needed from 
time to time 
-3 
 
Airway 
management 
needed 
throughout 
procedure 
 
 
 
 
Respiratory 
adverse events 
-1 
 
SpO2< 90% 
-1 
 
Signs of 
respiratory 
obstruction, 
wheezing, 
snoring 
-1 
 
Respiratory 
pauses > 10s, 
rib retraction 
 -2 
 
Apnoea or 
episodes of 
apnoea 
 
Haemodynamic 
adverse events 
-1 
 
BP decrease of 
>33% from 
baseline 
-1 
 
Pulse rate > 
160/min. 
  
Table 5 
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5.13.3.1. Level of Consciousness. 
 
 The results are shown in graph 5.13.3.1 below and were as follows:  
• 186 children were scored as 0, and  
• 14 as -1.  
 None of the children were rated as either -2 or -3, as this is not conscious sedation, and 
these levels are closer to anaesthesia, and is not safe outside of a theatre.  
 
This research study clearly shows that paediatric sedation was done according to the 
sedation guidelines if we look at the level of consciousness, which in effect means sedation. 
  
 
Graph 5.13.3.1 
 
5.13.3.2. Maintenance of the Airway. 
 
 The patient’s airways were evaluated according to the level of interference that was needed 
from the sedation practitioner to keep it patent and without obstruction.  The scoring chart 
is shown in table 5 (p. 71) .  
• The total number of children who were able to control their own airway (self 
preservation) without any interference was 78.5%, and this shows that conscious 
sedation is possible in children if we also take into account the scores discussed 
under the level of consciousness.   
• A total of 16% of children needed minimal interference to keep their airways open.  
This usually was necessary when the operators depressed the chins when working 
on the bottom teeth.  None of these children desaturated.   
• The next group of children under this category was scored as -2.  These children 
needed airway management e.g. chin lift from time to time.  They constituted 4% of 
the study group.   
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• The last group which were evaluated as 1.5% of the children under this category 
needed constant airway management e.g. chin lift.  This could be due to the fact that 
some of these children were done at deeper levels of sedation, because the children 
were not co-operative when doing conscious sedation. Another possibility may be a 
difficult airway e.g. tonsillar hypertrophy.  None of the children in this group 
received oxygen continuously.   
 
 
Graph 5.13.3.2 
 
5.13.3.3. Respiratory (breathing) Adverse Events. 
 
 Any respiratory adverse incident as defined in Table 5 (p 71) was scored as -1, apart from 
apnoea or periods of apnoea scored as -2.  This included desaturation below 90%, signs of 
respiratory obstruction, and respiratory pauses for more than 10 seconds.  Only 14 children 
had a respiratory adverse event.  Most of these were handled with only airway management 
as described above and using suction to get rid of secretions.  Of these 14 children, who 
constitute 7% of the study group, only 6, or 3%, needed oxygen administration to treat the 
respiratory adverse event.  In all the cases that needed oxygen, saturation was back to above 
90% within 30 seconds of administering the oxygen.  The incidence of coughing and 
desaturation is very closely linked to the expertise of the operator and their use of water.   
 
The researcher can come to the conclusion that all the respiratory adverse events were 
minor because correction of the causing event was done immediately and effectively.  The 
morbidity and mortality because of respiratory adverse events were 0%.   
 
See graph 5.13.3.3 (p.74) for the results.   
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Graph 5.13.3.3 
 
5.13.3.4. Haemodynamic Adverse Events. 
 
 These were also scored as -1 for any adverse event as can be seen in Table 5 (p 71).  These 
events are extremely rare in ASA 1 and 2 children during sedation.  This can also be seen in 
the results.   
 
A drop in blood pressure of more than 33% from the baseline, or a pulse rate of more than 
160 beats per minute was seen as a haemodynamic adverse event.  Haemodynamic adverse 
events were seen in 6% of children.   
• A total of 5% of them had a tachycardia of between 160 and 180 beats per minute.   
• 0.5% (one patient) had a pulse rate of more than 180 beats per minute.   
• 0.5% (one patient) had a drop in blood pressure of more than 33% from the first 
blood pressure reading.   
The one patient with the pulse rate of more than 180 per minute had a history of a cleft 
palate that was surgically repaired.  The mother gave a history that she does not tolerate any 
foreign objects in her mouth, which was very obvious when we inserted the bite block.  Her 
pulse rate was between 158 and 182 throughout the procedure.  This patient was not a good 
candidate for sedation, and should be done in theatre with general anaesthesia.   
See graph 5.13.3.4 for the graphic results.   
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Graph 5.13.3.4 
 
5.13.4. Efficacy 
 
The efficacy of the sedation technique was evaluated looking at the parameters shown in 
Table 6: (Patient factors influencing safety) 
 
 
 
Pain/Stress/ 
anxiety 
0 
 
Eyes closed or 
open, no signs 
of pain 
 
1 
 
Signs of 
complaining, 
sweating, 
frowning 
2 
 
Crying, tears, 
hysterical 
 
 
 
 
Movement 
0 
 
Quiet, 
purposeful 
movement 
 
1 
 
More 
movement but 
not interfering 
with surgery 
2 
 
Major 
movement, 
interfering with 
surgery 
3 
 
Uncontrolled 
movement, 
kicking or 
biting. Unable 
to work 
Physical signs 
of discomfort, 
tachycardia 
0 
 
Baseline pulse 
rate 
1 
 
Moderate 
tachycardia  
160 -180/min. 
2 
 
Severe 
tachycardia 
> 180/min. 
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The results will be discussed under the following headings:  
• Pain and stress/anxiety,  
• Movement and  
• Physical signs.    
 
5.13.4.1. Pain and Stress/Anxiety 
 
Pain and stress was mostly an indication of the anxiety level of the patients, how the 
patients reacted to the administration of the local anaesthetic, and the pressure they feel 
with extractions.  From the total of 200 patients: 
• 79.5% showed no signs of pain or stress. 
• 19% showed signs of complaining or frowning, mostly with the administration of 
the local anaesthetic. 
• 1.5% or three patients were crying or hysterical.  Two of the patients were 
extremely anxious and agitated from their arrival at the consulting room.  One of 
them settled down after a while into the procedure as he realized that he is not 
being hurt.  The third child was reacting very strongly to the bite block, and every 
time it was moved, she became hysterical.  This is the child who had the cleft 
palate repair.  
 
 
Graph 5.13.4.1 
 
The results above show that sedation is a effective alternative to general anaesthetic to 
perform painful and traumatic procedures in children.   
 
5.13.4.2 Movement 
 
Movement was the next indicator of the efficacy of the sedation that was evaluated.  This 
was scored as showed in table 6 (p 75).   
79.5 
19 
1.5 
0
20
40
60
80
100
0 1 2
Pe
rc
en
ta
ge
 o
f c
hi
ld
re
n 
(%
) 
Sedationist evaluation of pain and stress 
Efficacy: Pain and stress 
 
 
 
 
 77 
• 61.5% scored a 0, which means that the patients were quiet with purposeful 
movements.   
• 26.5% were moving a little bit more, but were still not interfering with the 
procedure.  This falls within our definition of conscious or moderate sedation.   
• The group that showed major movement was 12% of the study group.  Although 
these sedations were very difficult to do, the procedures were completed.  This 
shows again that paediatric sedation is not always easy.   
• None of the patients scored a 3, meaning that procedures would have to be 
cancelled.   
 
 
Graph 5.13.4.2 
 
The results above indicate that sedation is an effective treatment option for dental work in 
children.  We must keep in mind that a small percentage of children will always be difficult 
to manage with sedation.   
 
5.13.4.3 Physical Signs.  
 
Physical signs of discomfort were the last parameter of the evaluation of efficacy in graph 
5.13.4.3.  This was measured according to the pulse rate of the patients.  This correlates 
very well with the haemodynamic adverse events that were discussed under the topic of 
safety.   
• The largest group, 94.5% in graph 5.13.4.3 had baseline heart rates.   
• A total of 5% of the study group showed a moderate tachycardia of 160 – 180 beats 
per minute. 
•  Only 0.5% or one patient had a transient tachycardia of more than 180 beats per 
minute.  This is the same child with a cleft palate repair that has been mentioned 
previously.   
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Graph 5.13.4.3 
 
The last parameter in the efficacy evaluation also shows that sedation is an acceptable 
alternative treatment option for dental work in children as 94.5% of the children showed no 
signs of discomfort.  
  
5.14 PARENT EVALUATION 
 
The parents of the children were asked to complete a questionnaire before the child was 
discharged  (Annexure D, p100).  These questions will be discussed and the results shown 
on graphs in the section first questionnaire.   
 
The parents were also given a second questionnaire to complete the following day.  
(Annexure E, p 101).  Of these second questionnaires 64 were returned, and these results 
are included in the discussion and the graphs in the section second questionnaire.   
 
FIRST QUESTIONNAIRE 
Every parent filled out this questionnaire before their child was discharged.   
 
Question 1 and 2 – Normal Behaviour.  
 
Question one asked the parents about their child’s normal, usual behaviour and question 2 
asked the parents about their child’s behaviour after the sedation.  These questions were 
asked to see if there was any correlation between a child’s normal behaviour and how they 
behave after sedation.  The same questions were asked in question 2 after the sedation.   
 
The parents indicated that 36 or 18% of the children were hyperactive.  In the medical 
history questionnaire, only eight of the children were actually on Ritalin® as treatment for 
hyperactivity.  Hyperactive children are sometimes perceived to be difficult to sedate by 
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sedation practitioners, but in this study, only 4 of the 36 children who were hyperactive, 
were actually marked as being a difficult sedation.   
 
 
Graph 5.14.1 
 
 
Graphic 5.14.2 
 
In their opinion, 47 of the children were crying after the procedure.  This is not an abnormal 
response after administration of drugs in children.  They receive drugs, become awake in a 
strange environment, and often have visual disturbances, and their mouth is numb from the 
local anaesthetic.  This all may contribute to side effects.   
 
Only one child (0.5%) was aggressive after the sedation.  This child has not had a general 
anaesthetic before, so no comparison could be made.  Four of the children who had general 
anaesthesia before, were very aggressive after the anaesthetic.  None of these children 
showed any aggression after the sedation.   
 
 
36 
161 
3 2 1 0 
0
50
100
150
200
Hyperactive Normal Clingy Weepy Hysterical Lethargic
N
um
be
r  
of
 c
hi
ld
re
n 
 
Behaviour before sedation as indicated by parents 
Behaviour prior to sedation 
9 
115 
17 
47 
4 
17 
1 
0
20
40
60
80
100
120
140
Hyperactive Normal Clingy Weepy Hysterical Lethargic Aggressive
nu
m
be
r  
of
 c
hi
ld
re
n 
 
Behaviour after sedation as indicated by parents 
Behaviour after sedation 
 
 
 
 
 80 
Question 3 – Side-effects of Sedation. 
 Parents were asked to report possible side-effects after sedation.  The most common side-
effects were explained to the parents, and they were asked to mark those applicable to their 
child (possible side effects are shown in the graph).  There were no restrictions on how 
many they could report.  The following graph shows the results.   
 
 
Graphic 5.14.3 
 
• 49.5% of the parents thought that their children were drowsy after the sedation, 
where the sedation practitioner only evaluated 10.5% as drowsy.  This is due to the 
fact that the sedation practitioner marked the child as drowsy only when the 
drowsiness was excessive.  The parents were also called in to sit with their children 
as soon as the procedure was completed, and the children were not awake yet.   
• The incidence of blurred or double vision was 13%, and this is to be expected.  The 
incidence of side effects was more or less the same as evaluated by the sedation 
practitioner and the parents.   
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Question 4 – Level of sedation (consciousness) after procedure. 
 
The parents were asked to evaluate the level of sedation (consciousness), 30 minutes after 
the sedation. This is an indication of recovery of the children. 
 
Graphic 5.14.4 
 
• About 38% of parents evaluated their children as awake and orientated after 
sedation.   
• 40.5% of children were still drowsy, but awake.   
• 20% of the children were sleeping but easy to rouse.   
• Only three children (1.5%) were difficult to rouse, but they still maintained their 
airway and breathing.  The results are shown in the graph 5.14.4.   
The above again indicates that post-operative recovery care is extremely important in 
children. 
 
Question 5 – Financial Implications. 
 
The parents were asked if financial implications will play a role in their decision whether to 
have sedation or anaesthesia for their children.  Four parents did not answer the question.   
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38 40.5 
20 
1.5 
0
10
20
30
40
50
Awake, orientated Drowsy Sleepy, easy to rouse Sleepy, difficult to
rouse
Pe
rc
en
ta
ge
 o
f c
hi
ld
re
n 
(%
) 
Level of sedation post-operative as indicated by the parents 
Level of sedation after procedure 
49.5 48.5 
48
48.5
49
49.5
50
Yes No
Pe
rc
en
ta
ge
 o
f c
hi
ld
re
n 
(%
) 
Parents stating whether financial implications is important 
Financial implications 
 
 
 
 
 82 
The parents who answered the question responded as follows: 
• 97 said that the financial implications did not play a role in their decision.   
• 99 said that finances did make a difference.   
• This indicated that 49.5% of the parents considered the financial implications in 
their decision whether there child will go to theatre for dental work, or have 
sedation in the consulting room.  In the current financial market, this confirms how 
important cost savings are to parents.   
 
Question 6 – Sedation Experience 
 
The parents were asked to rate the sedation experience on a VAS scale from 1 to 10, where 
10 is excellent and 0 poor.  The results are displayed on graph 5.14.6 
 
 
Graph 5.14.6 
 
• The lowest score indicated the sedation experience as three.   
• One parent gave a rating as four.  Both these parents were expecting something 
similar to anaesthesia, children will be “knocked out”.  It is important for a 
successful sedation for the parents to have realistic expectations.  This can only be 
achieved by communication with the parents and explaining the differences 
between sedation and general anaesthesia. The operator also needs to explain the 
procedure to the parents.  
• Most of the parents were satisfied with their child’s sedation experience, since 96% 
of the parents rated the sedation between 8 and 10.   
 
Question 7 – Anaesthesia versus Sedation 
 
With this question the parents were asked whether their children had an anaesthetic before, 
and if they had, would they prefer sedation or anesthesia if it is possible to choose.  The 
study group consisted of patients who are mostly on medical aid.  In this group 75.5% of 
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the patients had previous exposure to general anaesthesia.  This gave the parents a good 
platform to compare sedation and general anaesthesia.  Of the 151 parents who answered 
yes to this question, five said either sedation or general anaesthesia would be acceptable.  
These five answers were excluded in graph 5.14.7 that shows the choice between sedation 
and theater.   
 
 
Graph 5.14.7 
 
146 parents answered this question as follows:   
• 14 parents chose general anaesthesia (7%). 
• 132 chose sedation (66%).  This implies that 2 out of every 3 parents would prefer 
sedation for dental work.   
 
SECOND QUESTIONNAIRE 
 
The second questionnaire (Annexure E, p101) was given to the parents to complete 24 
hours after the sedation.  Only 65 of these questionnaires were returned and were included 
in the study.  In this section only 3 of the questions will be reported on, as it will contribute 
to the efficacy and safety aspect of this study, namely: 
• Question 3: Level of sedation on the journey home. 
• Question 4: Level of sedation 24 hours after sedation. 
• Question 6: Child’s memory. 
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Question 3 – Level of Sedation (consciousness). 
 
This question was asked to clarify the level of sedation (consciousness) on their journey 
home.  Results are displayed in graph 5.14.10. 
 
 
Graph 5.14.8 
 
• Only one parent reported that the child was sleeping and difficult to rouse.   
• Most of the children were drowsy, namely 44%.  Parents were warned to look after 
the airway of the children on the journey home. 
 
The response of the one parent that their child was difficult to rouse, again emphasizes the 
point of the importance of discharge criteria.  Children who are not stimulated can slip into 
a deeper level of sedation, and this can lead to morbidity and mortality in pediatric 
sedation.   
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Question 4 – Level of Sedation (consciousness). 
 
This question evaluated the level of sedation 24 hours after the sedation.  Results are shown 
in graph 5.14.9 
 
 
Graph 5.14.9 
 
• 97% of the children were awake and oriented.   
• 3% were sleepy but easy to rouse.   
 
Question 6 – Child’s Memory. 
 
This question was asked to evaluate the child’s memory (recollection) of the procedure.  
The following questions were asked.  
 
•  Whether they could remember the start of the intravenous injection.   
• Whether they were aware of the injection in the gum. 
• Whether they had discomfort during the procedure. 
• Whether they had pain during the procedure.  
• Whether they could remember the journey home.  
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The results are shown in graph 5.14.10 
 
 
Graph 5.14.10 
• Although 32% of children said that they could remember the injection, no one said 
that they had any discomfort during the procedure.  
• 1.5% could remember the injection in the gum. 
• Only one child stated that he/she had pain during the treatment.   
• 31% of the children did not even remember the journey home.   
 
These questions, that were answered by the parents the day after the procedure, again 
shows the safety and efficacy of sedation for dental procedures in children.   
 
Comments made by the parents are included in Annexure  J(p.106).    
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CHAPTER SIX 
 
CONCLUSIONS AND RECOMMENDATIONS 
 
6.1 INTRODUCTION 
In the literature review for this study, the researcher looked at articles that report sedation 
on a total of more than one thousand eight hundred paediatric patients.  
• None of these studies showed any serious morbidity and the mortality rate was zero.   
• Minor adverse events were mostly respiratory in nature which was rated as minor 
with no escalation in care.   
• Results were excellent because all of these studies were done in large academic 
centres where the guidelines for paediatric sedation were followed, from the pre-
operative evaluation, dedicated monitoring throughout the procedure and proper 
recovery and discharge criteria.   
 
The design of this study was planned to evaluate the safety and efficacy of sedation 
according to certain parameters for children between two and ten years of age, with the 
focus on sedation done in the dentist’s chair/office outside of a theatre environment.   
 
Both the operator and the sedation practitioner used tables with certain parameters and 
values to score the efficacy and safety of sedations consequently.  Conclusions from this 
study will be discussed under the following headings: General, Safety, Efficacy and Drugs.  
The discussion of the recommendations will follow with final comments at the end.   
 
6.2 CONCLUSIONS 
 
6.2.1 GENERAL 
 
Patient selection: Children from 3 years of age that fall in an ASA 1 or 2 category is 
suitable for sedation in the dentist’s office.  Younger children e.g. between 2 and 3 years 
should be evaluated by the sedation practitioner beforehand.  The operator/dentist should be 
aware of body mass index guidelines to avoid obese children being booked on the sedation 
list.   
 
Instructions: All the parents should receive verbal as well as written instructions to 
prepare for the sedation procedure.  The Emla patch used as local anaesthetic for 
cannulation and the nul per os requirements should be explained.   
 
Pre-medication: Midazolam and ketamine are good choices to use as pre-medication.   
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Intravenous cannulation: Most children are afraid of needles, and using pre-medication 
and Emla patches makes the placement of the intravenous cannula easier for the child, the 
parent and the sedation practitioner.   
 
Techniques used: Different sedation techniques are available to use for paediatric 
sedation.  The decision of whether a bolus or continues infusion technique should be used, 
must be decided by the sedation practitioner taking into consideration the length and type 
of the planned procedure.   
 
Monitoring: Pulse rate, saturation, respiratory rate and blood pressure should be monitored 
throughout the procedure.  Vigilant observation from the sedation practitioner is extremely 
important.   
 
Resuscitation: All necessary resuscitation equipment and an AED suitable for paediatric 
use should be unpacked and available for every paediatric sedation.   
 
Reasons for surgery: Fillings, pulpotomy’s, extractions, tooth exposure, frenectomy’s and 
root canal treatments are suitable procedures that can be done for children with sedation in 
the dentist’s chair.   
 
Time of procedures: The majority of sedation procedures are short in duration. This 
obviously will add to the safety of paediatric sedation practice.   
 
Failed sedation: The failure rate is extremely low and warrants no further comment than to 
say that paediatric sedation can be extremely difficult.  There is no factor that could be 
found to predict a difficult sedation in ASA 1 or 2 children.  It is no shame to abandon 
sedation in the interest of safety and to suggest general anaesthesia for certain patients.   
 
Financial implications: In the current economical climate, financial implications of 
medical care are very important.  Sedation is a cost effective alternative to general 
anaesthesia and theatre costs.   
 
6.2.2 SAFETY 
 
Level of consciousness: The children were reacting to vocal or light physical stimulation.  
This level of consciousness is required for moderate (conscious) sedation in all guidelines 
for sedation outside of the operating room.   
 
Evidence of airway compromise: The majority of children should be able to maintain 
their own airway or need only minimal interference to keep their airway open.  This also 
confirms that moderate or conscious sedation is practised. 
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Respiratory adverse events: Airway management should be applied timeously to prevent 
serious complications, morbidity and mortality, as most of the adverse events in children is 
respiratory in origin.  The administration of oxygen should be considered early.  When 
using very low dosages of sedation medication, respiratory depression can be avoided.  
Tachypnoea pre-operatively is an important observation because it can indicate a 
respiratory infection.   
 
Haemodynamic adverse events: An increase in pulse rate is the most common 
haemodynamic adverse event.  This is commonly seen in very anxious children.  The 
tachycardia can be treated by adjusting the level of sedation to procedural sedation until the 
pulse rate stabilizes.  Most of the painful stimulation in dental sedation is in the beginning 
of the procedure with the administration of the local anaesthetic.   
 
Wilson sedation scale: The sedation level of children can be evaluated according to the 
Wilson sedation scale.  Children should respond to verbal or mild physical stimulation.  
These levels are still moderate sedation, which is acceptable in an office setting outside of a 
theatre environment.   
 
Steward recovery scale: This recovery scale is widely used and easy to implement.  It is 
essential to have set discharge criteria to prevent complications after discharge of the 
children.  Care should be taken to make note of this score on the monitoring chart in case of 
medico-legal consequences.   
 
Fasting guidelines: Fasting for 4 hours prior to the procedure is sufficient in children.   
 
Post-operative care: Post-operative care is crucial, because the stimulation from the 
procedure is absent and children can slip into deeper levels of sedation.   
 
Side-effects: Post-operative side-effects are inevitable when administering medication to 
children.  Children are usually anxious in a strange environment, and receive drugs.  This 
all contribute to side-effects.  The low incidence of side-effects in sedation practice is due 
to the low dosages of medication used.   
 
In this research study no serious adverse events were seen mainly due to: 
• Sedation being done by an experienced sedation practitioner 
• Pre-operative evaluation and assessment done on all patients 
• Careful and discriminate use of drugs 
• Behavioural management techniques used 
• Monitoring 
• Children not being discharged before meeting the required discharge criteria 
• Empowerment of the parents. 
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With all the parameters mentioned above, the sedation practitioner could come to the 
conclusion that paediatric sedation is safe in an office setting.   
 
6.2.3 EFFICACY 
 
This study evaluated the efficacy of the sedation procedure from the viewpoint of the 
operator/dentist, sedation practitioner and the parent. 
 
Operator:  
• The dentists found the procedures mostly easy to complete. 
• They could deliver good quality work with the children keeping still and being 
quiet.   
• This is extremely important and what we want for paediatric sedation. 
 
Sedation practitioner:  
• Pain and stress. 
Sedation is an effective alternative to general anaesthetic to perform dental procedures in 
unco-operative and anxious children.   
 
• Movement  
Even with slight movement the dental procedures could be completed satisfactory.  
Minimal movement is expected in moderate (conscious) sedation and actually confirm that 
the level of sedation is moderate (conscious) sedation. 
 
• Physical signs that included monitoring the pulse rate.   
Monitoring the children for signs of distress is important to ensure that they don’t 
experience pain or discomfort.  The pulse rate can be used as an indicator of physical 
distress in the children.   
 
With all the parameters mentioned above the sedation practitioner could come to the 
conclusion that sedation in children is possible and efficacious.   
 
Parents:  
• Most of the parents experienced sedation in a positive way.   
• The children’s behaviour was normal after 24 hours. 
• The side effects in their children are all acceptable in sedation practice.  No serious 
side effects occurred.   
• The children were awake or sleeping but easily rousable after the sedation.   
• The parents indicated that the financial implications will influence their decision 
whether to have sedation or general anaesthetic for dental work for their children.   
• The parents would prefer sedation in the dentist’s room to theatre.   
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6.2.4 DRUGS 
 
The drugs used included pre-medication that were administered according to the age of the 
children.  Children younger than six years received 3.75mg of midazolam and children 
older than six years received 7.5mg of midazolam.  Some of the children received a second 
pre-medication that included ketamine 2mg/kg per os if they were not co-operative for 
placement of the intravenous cannula.   
 
A bolus technique with ketofol was used in 7 patients.  These procedures were planned to 
last 20 minutes or less.  The remaining 193 patients received a continuous infusion of the 
following mixture: each ml of solution contained propofol 8.3mg, mepyramine maleate 
1mg, ketamine 2mg and sufentanil 0.2µg.  The infusion rate was between 2 to 4mg/kg/h. 
 
• The advantage of using a continuous infusion technique is that the level of sedation 
can easily be titrated to a deeper level if needed or a more conscious level if the 
patient slipped into an unintended deeper level of sedation. Some of the children 
were done at a deeper level of sedation, but still without any serious complications. 
 
• We need to follow international sedation guidelines for the paediatric population.  
 
• The researcher wants to confirm statements in the literature that deep sedation being 
planned and performed by a trained sedation practitioner does not carry higher risk 
than conscious sedation, specifically when a pre-operative risk assessment was 
performed. [13]  
 
• However, whenever excessive movements are encountered, the possibility of deep 
sedation must always be kept in mind.  This is not according to the SASA 
guidelines on paediatric sedation, but it is sometimes difficult when doing sedation 
and one is faced with either cancelling the case or going to a deeper level of 
sedation for a short period of time. 
 
• This shows that one must always consider that sedation is not the only option for 
children for dental procedures, in certain cases general anaesthesia will have to be 
considered.  
 
• Throughout the literature studies concerning sedation shows that there are many 
different regimes of medications that were used and compared to each other.  Some 
combinations of drugs were more efficacious than others.   
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• The type of procedure also influences the choice of drugs.  Patients undergoing 
painful procedures will need more analgesic medication where less painful 
procedures will need more sedative drugs.  
 
• It is evident from the above that sedation practitioners must have the knowledge and 
skills with administration of drugs.  The skill of the sedation practitioner and his/her 
knowledge of the specific drugs they use, are much more important than specific 
sedation drug regimes.   
 
6.3 RECOMMENDATIONS 
 
The implementation of a mobile sedation service requires careful planning.  The following 
components are of utmost importance: 
 
Sedation practitioner:  
• The sedation practitioner has to be experienced in office based sedation outside of 
the operating theatre.   
• Post-graduate training is essential specific in paediatric sedation that can sometimes 
be extremely difficult.   
• Working towards an accreditation system that is overseen by the Medical and 
Dental Council of South Africa would be a goal to set, specifically because we do 
have a post-graduate training course available.  In South Africa there is no legal 
regulation currently as to who can perform paediatric sedation in the office based 
setting.  SASA guidelines were published in 2010 that states very clearly who, 
where and how paediatric sedation can be done, but these are still only guidelines.   
 
Operator:  
• The operator/dentist has to be the important link in the sedation service to patients.  
This usually is the patients’ first contact with the sedation procedure.  It is important 
that the operator explains the procedure to the patients so that they do not have 
expectations that cannot be met e.g. “I want my child to be knocked out”. (see 
comments of parents (Annexure K, p 107).   
• The operator/dentist should also be trained in basic life support (BLS) and airway 
management.  The fact that the dentist/operator is skilled in airway management 
usually makes the sedation easier to do.   
• In cases of emergency they have to help to treat the adverse event.   
• The operator/dentist also has to accept the limitations of sedation and the fact that 
they need to adjust their usual method of work to the sedation.   
• The experience of the operator/dentist also plays a role in the safety and efficacy of 
paediatric sedation.   
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Patient Selection:  
• The operator/dentist is responsible for offering sedation as an option to their 
patients.  For this reason they must have a good understanding of selection criteria 
for sedation patients.  The final decision whether to do a patients stays the 
responsibility of the sedation practitioner.  In the office based setting only ASA 1 
and 2 patients are suitable, as according to all international guidelines.   
• Anxiousness of the patient is extremely important.  The patient who is phobic about 
needles is not a good choice for sedation because we have to start with the 
placement of an intravenous cannula.  Unfortunately we do see patients for sedation 
who are not really suited because of financial implications.   
 
Facility/Office:  
• The facility/office where the sedations will be done must be easily accessible.  An 
office on the second floor of buildings is questionable in their suitability, 
specifically when emergency and escalation of care occur.   
• The size of the office must also be large enough to accommodate the sedation 
practitioner and all the equipment needed to perform office based sedation.   
 
Communication with parents:  
• It is important to give the patients written as well as oral instructions in preparation 
for sedation.   
• Fasting guidelines must be adhered to.  In this study the patients were fasting for 4 
hours prior to the sedation procedure.  Fasting can be difficult in children and the 
reasons need to be explained to the parents.   
• It is also imperative to communicate with parents and explain the concept of 
sedation to them.  They need to understand that there child is not going to be 
“knocked out”, but that they will still be able to breath and even move a little bit, 
without feeling pain.   
• In the cases of long procedures, parents should be informed that their child might 
need a second appointment to complete the work if they become restless.   
• The parents should be warned about commonly occurring side effects, e. g. double 
vision.   
 
Procedures and time management:  
• In dentistry, any procedure that can be done in the dentist’s chair with local 
anaesthetic can be done with sedation.  The reasons for the procedures in this study 
included the following: fillings, extractions, pulpotomy’s, tooth exposures, 
frenectomy’s and even root canal treatments.   
• For children, sedation is a very good option for procedures that can be unpleasant 
when the child is awake in the office chair. 
• Time management should be applied when sedating children. 
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Emergency care:  
• Awareness of the emergency care availability in the area where the sedation is 
performed is essential in the case of escalation of care.   
 
Adverse events: To prevent serious adverse events when sedating children the following 
considerations are very important:  
1. The sedation must be done by an experienced sedation practitioner 
2. Pre-operative evaluation and assessment must be done on all patients 
3. Drugs must be used carefully and discriminately 
4. Behaviour management techniques must be used together with pharmacotherapy 
5. Monitoring throughout the procedure is crucial 
6. Discharge criteria must be implemented and followed strictly 
7. The parents must be able to make an informed choice concerning the treatment of 
their children.  This can only be done with good two way communication.   
 
Drug use:  
• The use of drugs in children should be done very carefully.   
• Titration is extremely important.   
• The sedation practitioner should be knowledgeable about the drugs he/she is using.   
• Sedative drugs like midazolam, propofol and sufentanil must be titrated to avoid 
respiratory suppression.   
• When using ketamine the following should be kept in mind: 
1. Emergence reactions can be seen in recovery, including vivid and often 
unpleasant dreams, confusion, hallucinations and irrational behavior.  
Children appear to be less sensitive.  The incidence of emergence reactions 
is controversial - and is seen relatively seldom with the sedation dosages of 
ketamine.   
2. Ketamine should be injected slowly to avoid respiratory depression.   
3. Diplopia and nystagmus may occur.  It is good practice to warn especially 
the parents of children about this.  They can be very upset if the child 
complains that he/she cannot see.   
 
Recovery and discharge:  
• In all mobile sedation practices it is imperative that children should be recovered 
and discharged according to international discharge criteria to avoid post-operative 
morbidity and mortality.   
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6.4 FINAL COMMENTS 
In conclusion, the researcher showed: 
• That multidrug intravenous sedation can be administered to children safely and 
effectively.  It is most important to adhere to all guidelines concerning the ability to 
rescue a patient when an adverse event does occur.  
• Furthermore, the selection of patients is critical when working in an office based 
environment.   
• There are a number of different multidrug techniques that have been published.  The 
researcher wants to emphasize the point that the combinations of drugs used are less 
important than the experience and training of the sedation practitioner.   
• The question whether conscious sedation can be done safely and effectively in an 
office environment for children between 2 and 10 years of age was answered very 
definitely as yes in this study.  Moderate/conscious sedation is possible in children.  
It is safe to perform outside a theatre environment.   
 
6.5 FURTHER RESEARCH 
 
The following topics can be considered for further research: 
 
• Multicentre studies to compare safety and efficacy data. 
• Comparisons of different age groups as to the prevalence of adverse events.  
• Multidrug intravenous drug regimes comparisons.  
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ANNEXURES 
 
ANNEXURE A: Consent form 
 
Doctor performing procedure:________________________________ Date:________ 
 
I, the undersigned, hereby state that I am legally competent to give consent for this 
procedure and am aware of the nature and scope of the risks of the procedure and the 
sedation.   
I give permission to the doctors concerned to take any blood tests as may deem necessary 
in the event of contamination of blood or body fluids to the health worker concerned.   
I accept full responsibility for the account in the event that my medical aid should, for 
whatever reason, fail to settle the account in full.   
 
PATIENT NAME: ____________________________ Signature:________________ 
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ANNEXURE B: Ethical statement 
 
PATIENT INFORMATION 
 
You are invited to take part in a research study by using information gained during the sedation procedure of 
your child. The efficacy and safety of sedation in children younger than 10 years will be recorded. 
I, the undersigned_______________________________________ 
ID___________________________________________________ the mother/father 
of_____________________________________ 
Address:______________________________________________ 
 
A.    I confirm that: 
1. I was invited by Dr. E. M. Swart to take part in this research study, as part of a thesis for the 
research MSc in sedation at the University of the Western Cape Dental department. 
2. It has been explained to me that: 
  My child will undergo an intravenous sedation for a dental procedure to relief 
his/her pain and anxiety. 
 The drugs will be given intravenously, either by bolus injection or using an infusion, 
depending on the length of the planned procedure. The child will receive an Emla 
patch that should be placed over a suitable vein two hours before the time. This will 
give local anaesthesia to make the cannulation a painless procedure. 
 The medication used for the sedation is not new. The same medication has been used 
in anaesthetic practice for many years. Dr. Swart has been practising this technique 
since 2002. 
 The efficacy and safety of sedation will be evaluated according to set tables and 
questionnaires. The viewpoint of the dentist, the seditionist, and the parent 
accompanying the child will be taken into consideration.   
 I have been warned that any drug can cause side effects. The medication used may 
cause dry mouth, dizziness, double vision, red eyes, rarely nausea and vomiting. 
 My child will be monitored very carefully. 
3. 200 Children will partake in this project over the next two years. 
4. It has been explained to me that my child will make an important contribution to medical 
knowledge, so that this technique may be used elsewhere to help other children through 
unpleasant experiences. 
5. All information regarding my child will be kept in strict confidence. The results will be 
published in a medical journal for the benefit of other researchers. 
6. I hereby confirm that I have been told that if I change my mind after first deciding on the 
sedation, the dentist will offer me the most suitable alternative treatment. The care of my 
child will not suffer in any way. Dr. Swart may also withdraw my child from the study if it is 
in his/her best interest. 
7. I have not been forced to participate in this study. 
8. Participation in this study will not mean any extra costs for me. The cost of the sedation will 
be charged either to the medical aid or the patient as usually. 
B.   I hereby declare that I volunteer to participate in this study. 
PARENT/LEGAL GAURDIAN 
 
Signed at ___ ________________________________ on _____________________________________  
Parent ______ ________________________________ witness _________________________________  
 
RESEARCHER 
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I ___________________________________________ declare that the information in this document was 
explained to the parent/guardian in his own language and that he/she understands everything. 
Signed at ____________________________________ on _____________________________________  
Researcher ___________________________________ Witness_________________________________ 
IMPORTANT INFORMATION: 
If you need any additional information, or in an emergency situation, please contact: DR. E. M. Swart  
0828512083.  
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ANNEXURE C: Instructions 
 
PRE-INTRAVENOUS SEDATION INSTRUCTIONS 
 
1. Please arrive at least 30 minutes before your appointment. This is so that we can give 
your child a Dormicum tablet. This medication will make them drowsy, so that we 
can start the intravenous line easily. 
2. Please wear comfortable clothes with wide sleeves allowing easy access to the elbow 
region. 
3. If you wear contact lenses, please bring your lens container with you, as you may be 
asked to remove your contact lenses. 
4. Please do NOT eat or drink for 4 hours before your appointment. 
5. A responsible adult must accompany the children and look after them for the rest of 
the day. Adults must arrange for someone to drive them home and stay with them. 
6. The children should be kept quiet for the rest of the day, and not partake in any 
activities that require balancing or concentration. 
7. If you take chronic medication on a regular basis, please inform the sedation 
practitioner, so that he/she can decide whether you should take your medication 
before the sedation. 
 
 
POST SEDATION INSTRUCTIONS 
 
1. Please do NOT take any alcohol for the remainder of the day. 
2. If you are taking regular medication, please ask the sedation practitioner when you 
should continue to take them. 
3. For PAIN relief you may take Paracetamol, Ponstan or Myprodol, depending on your 
personal preference and/or tolerance, unless your dentist or sedation practitioner has 
instructed you otherwise. 
4. The sedation may produce AMNESIA. This is temporary, lasting sometimes for a 
few hours. 
5. You may have clear fluids when instructed to do so by the sedation practitioner or 
dentist. If you feel fine after having clear fluids, and the local anaesthetic has worn of 
you may then progress onto solids. Keep to soft foods for the rest of the day. 
6. You may feel tired and/or low for up to 24 hours after the sedation. 
7. In case of bleeding, apply a wet teabag to the bleeding socket and bite on the teabag 
for at least 20 minutes. 
8. We do not anticipate you having any medical problems, but should you become 
concerned about anything, however trivial it may seem, contact your sedation 
practitioner, Dr. Swart on 0828512083 or 011-3919015.  
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ANNEXURE D:  
PARENT QUESTIONNAIRE ONE 
Date _______________________ Name ___________________________________________________________  
Gender:   M / F 
Please answer the following: 
1. Which one of the following would best describe your child’s normal behaviour pattern? 
Hyperactive  
Normal  
Clingy  
Weepy  
Hysterical  
Lethargic  
 
2. After the sedation, which one would best describe your child’s behaviour pattern? 
Hyperactive  
Normal  
Clingy  
Weepy  
Hysterical  
Lethargic  
 
3. Side-effects that occur with sedation are listed below. Please mark the ones that your child suffered 
from, if any. 
Nausea  Confusion  
Vomiting  Pain  
Headache  Drowsiness  
Blurred/double vision  Hallucinations  
Restlessness  Prolonged sedation  
 
4. Level of sedation 30 minutes after sedation: 
Awake and orientated  
Drowsy  
Sleeping but easy to rouse  
Sleeping but difficult to rouse  
   
5. Today the financial implications of medical procedures are becoming more important. It is estimated 
that sedation costs R1 for every R11 of theatre costs. Will the costs involved influence your decision 
about having sedation? 
Yes  
No  
 
6. Please rate the sedation experience where 10 is the best. 
Poor 1 2 3 4 5 6 7 8 9 10 Excellent 
 
7.        Has your child had anaesthetics in theatre before?  Y/N. If  yes, and it is possible to do a  procedure 
with  sedation, what would you prefer?   
Sedation  
Theatre  
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ANNEXURE E 
PARENT QUESTIONNAIRE TWO 
Date _______________________ Name ___________________________________________________________  
Gender:   M / F 
1. 12 hours after the sedation, which one would best describe your child’s behaviour pattern? 
Hyperactive  
Normal  
Clingy  
Weepy  
Hysterical  
Lethargic  
2. Side-effects that occur with sedation are listed below. Please mark the ones that your child suffered 
from, if any. 
Nausea  Confusion  
Vomiting  Pain  
Headache  Drowsiness  
Blurred/double vision  Hallucinations  
Restlessness  Prolonged sedation  
 
3. Level of sedation during your journey home: 
Awake and orientated  
Drowsy  
Sleeping but easy to rouse  
Sleeping but difficult to rouse  
 
4. Level of sedation 12 hours after the sedation: 
Awake and orientated  
Drowsy  
Sleeping but easy to rouse  
Sleeping but difficult to rouse  
 
5. Did your child’s behaviour after the sedation correlate with his/her normal behaviour patterns? 
Yes  
No  
 
6. Did your child have any memory of the following? 
 Yes No 
Needle in arm or hand   
Injection in the gum   
Discomfort during treatment   
Pain during treatment   
Journey home   
 
7. Please rate the sedation experience where 10 is the best. 
Poor 1 2 3 4 5 6 7 8 9 10 Excellent 
 
   
8. If you have any comments or suggestions, please write them down. 
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ANNEXURE F: Steward Recovery Scale 
 
 
PARAMETER FINDING POINTS 
  Consciousness   Awake   2 
     Arousable and responding to      
stimuli 
1 
     Not responding to stimuli   0 
  Airway   Coughing on command or crying   2 
   Maintaining good airway and 
breathing easily  
  1 
   Airway requires maintenance   0 
  Movement   Moving limbs purposefully   2 
   Non-purposeful movements   1 
   Not moving   0 
 
Interpretation:   
 ~ minimum score 0:  fully anesthetized 
 ~ maximum score 6:  fully recovered 
(Steward: 1975:111).   
 
STEWARD, D.J. A simplified scoring system for the post-operative 
 recovery room. Canad Anaest Soc J. 1975;22:111-113. 
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ANNEXURE G: Wilson Sedation Scale 
 
WILSON SCALE 
 
1 Fully awake and oriented 
2 Drowsy 
3 Eyes closed but rousable to command 
4 Eyes closed but rousable to mild physical stimulation (earlobe tug) 
5 Eyes closed but unrousable to mild physical stimulation 
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ANNEXURE H: Health Questionnaire 
Please turn to next page 
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ANNEXURE I: Spearman Correlation Reports 
Please turn to next 2 foldout pages. 
#nulle 1 0.0000
2 0.0000
3 0.0000
4 0.0000
Correlation Report
Spearman Correlations Section    (Pair-Wise Deletion)
AGE WEIGHT Dur_Sedation_Moved
Dur_Surge
ry_moved Puls_start
Pul_Diff_
10_S Mx_m_Puls Sis_Mx_M Dia_Mx_M
Mean_SDia_
Mx_M SatU_Mx_M Rp_Diff_10_S ResP_Mx_M
AGE 1 0.847 -0.100 -0.115 -0.468 0.051 0.003 -0.142 -0.051 -0.033 -0.021 0.113 -0.100
0 0.0000 0.1587 0.1037 0.0000 0.4740 0.9658 0.0450 0.4718 0.6462 0.7640 0.1097 0.1600
200 200 200 200 200 200 200 200 200 200 200 200 200
WEIGHT 0.847 1 -0.105 -0.121 -0.493 0.081 -0.015 -0.140 -0.051 -0.038 0.032 0.116 -0.097
0.0000 0 0.1389 0.0876 0.0000 0.2531 0.8279 0.0479 0.4764 0.5971 0.6566 0.1028 0.1739
200 200 200 200 200 200 200 200 200 200 200 200 200
Dur_Sedation_Moved -0.100 -0.105 1 0.984 -0.023 -0.103 0.383 0.488 0.422 0.429 0.380 -0.097 0.419
0.1587 0.1389 0 0.0000 0.7414 0.1475 0.0000 0.0000 0.0000 0.0000 0.0000 0.1706 0.0000
200 200 200 200 200 200 200 200 200 200 200 200 200
Dur_Surgery_moved -0.115 -0.121 0.984 1 -0.018 -0.116 0.376 0.480 0.396 0.406 0.373 -0.079 0.412
0.1037 0.0876 0 0 0.7998 0.1027 0.0000 0.0000 0.0000 0.0000 0.0000 0.2686 0.0000
200 200 200 200 200 200 200 200 200 200 200 200 200
Puls_start -0.468 -0.493 -0.023 -0.018 1 -0.215 -0.133 0.119 0.158 0.164 0.088 -0.059 0.092
0.0000 0.0000 0.7414 0.7998 0 0.0023 0.0599 0.0929 0.0255 0.0206 0.2128 0.4103 0.1949
200 200 200 200 200 200 200 200 200 200 200 200 200
Pul_Diff_10_S 0.051 0.081 -0.103 -0.116 -0.215 1 0.233 0.044 0.0341 -0.0114 -0.101 0.209 0.134
0.4740 0.2531 0.1475 0.1027 0.0023 0 0.0009 0.5391 0.6316 0.8723 0.1543 0.0029 0.0595
200 200 200 200 200 200 200 200 200 200 200 200 200
Mx_m_Puls 0.003 -0.015 0.383 0.376 -0.133 0.233 1 0.279 0.193 0.166 0.105 -0.006 0.315
0.9658 0.8279 0.0000 0.0000 0.0599 0.0009 0 0.0001 0.0062 0.0185 0.1379 0.9374 0.0000
200 200 200 200 200 200 200 200 200 200 200 200 200
Sis_Mx_M -0.142 -0.140 0.488 0.480 0.119 0.044 0.279 1 0.627 0.725 0.248 -0.071 0.352
0.0450 0.0479 0.0000 0.0000 0.0929 0.5391 0.0001 0 0.0000 0.0000 0.0004 0.3197 0.0000
200 200 200 200 200 200 200 200 200 200 200 200 200
Dia_Mx_M -0.051 -0.051 0.422 0.396 0.158 0.034 0.193 0.627 1 0.889 0.305 -0.048 0.403
0.4718 0.4764 0.0000 0.0000 0.0255 0.6316 0.0062 0.0000 0 0.0000 0.0000 0.5000 0.0000
200 200 200 200 200 200 200 200 200 200 200 200 200
Mean_SDia_Mx_M -0.033 -0.038 0.429 0.406 0.164 -0.011 0.166 0.725 0.889 1 0.300 -0.088 0.334
0.6462 0.5971 0.0000 0.0000 0.0206 0.8723 0.0185 0.0000 0.0000 0 0.0000 0.2141 0.0000
200 200 200 200 200 200 200 200 200 200 200 200 200
SatU_Mx_M -0.021 0.032 0.380 0.373 0.088 -0.101 0.105 0.248 0.305 0.300 1 -0.069 0.172
0.7640 0.6566 0.0000 0.0000 0.2128 0.1543 0.1379 0.0004 0.0000 0.0000 0 0.3296 0.0146
200 200 200 200 200 200 200 200 200 200 200 200 200
Rp_Diff_10_S 0.113 0.116 -0.097 -0.079 -0.059 0.209 -0.006 -0.071 -0.048 -0.088 -0.069 1 0.130
0.1097 0.1028 0.1706 0.2686 0.4103 0.0029 0.9374 0.3197 0.5000 0.2141 0.3296 0 0.0666
200 200 200 200 200 200 200 200 200 200 200 200 200
ResP_Mx_M -0.100 -0.097 0.419 0.412 0.092 0.134 0.315 0.352 0.403 0.334 0.172 0.130 1
0.1600 0.1739 0.0000 0.0000 0.1949 0.0595 0.0000 0.0000 0.0000 0.0000 0.0146 0.0666 0
200 200 200 200 200 200 200 200 200 200 200 200 200  
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#nulle 1 0.0000
2 0.0000
3 0.0000
4 0.0000
Correlation Report
Spearman Correlations Section    (Pair-Wise Deletion)
AGE WEIGHT Pulse  start Duration
Averg 
Pulse
Averg 
SisT
Averg 
DiasT
Averg 
MeaN
Averg_S
atU
Averg 
ResP
AGE 1 0.847 -0.468 -0.112 -0.446 0.386 0.217 0.294 0.058 -0.187
0 0.0000 0.0000 0.1137 0.0000 0.0000 0.0020 0.0000 0.4165 0.0081
200 200 200 200 200 200 200 200 200 200
WEIGHT 0.847 1 -0.493 -0.114 -0.495 0.435 0.246 0.335 0.027 -0.170
0.0000 0 0.0000 0.1078 0.0000 0.0000 0.0004 0.0000 0.7074 0.0163
200 200 200 200 200 200 200 200 200 200
Puls_start -0.468 -0.493 1 0.004 0.772 -0.113 -0.022 -0.065 -0.226 0.348
0.0000 0.0000 0 0.9547 0.0000 0.1125 0.7582 0.3570 0.0013 0.0000
200 200 200 200 200 200 200 200 200 200
Duration -0.112 -0.114 0.004 1 0.111 -0.058 -0.180 -0.155 -0.118 -0.096
0.1137 0.1078 0.9547 0 0.1191 0.4173 0.0107 0.0289 0.0957 0.1768
200 200 200 200 200 200 200 200 200 200
Averg_Pulse -0.446 -0.495 0.772 0.111 1 -0.015 0.064 0.033 -0.085 0.423
0.0000 0.0000 0.0000 0.1191 0 0.8370 0.3679 0.6437 0.2287 0.0000
200 200 200 200 200 200 200 200 200 200
Averg_SisT 0.386 0.435 -0.113 -0.058 -0.015 1 0.654 0.854 0.166 0.077
0.0000 0.0000 0.1125 0.4173 0.8370 0 0.0000 0.0000 0.0188 0.2771
200 200 200 200 200 200 200 200 200 200
Averg_DiasT 0.217 0.246 -0.022 -0.180 0.064 0.654 1 0.928 0.281 0.019
0.0020 0.0004 0.7582 0.0107 0.3679 0.0000 0 0.0000 0.0001 0.7937
200 200 200 200 200 200 200 200 200 200
Averg_MeaN 0.294 0.335 -0.065 -0.155 0.033 0.854 0.928 1 0.271 0.057
0.0000 0.0000 0.3570 0.0289 0.6437 0.0000 0.0000 0 0.0001 0.4195
200 200 200 200 200 200 200 200 200 200
Averg_SatU 0.058 0.027 -0.226 -0.118 -0.085 0.166 0.281 0.271 1 -0.003
0.4165 0.7074 0.0013 0.0957 0.2287 0.0188 0.0001 0.0001 0 0.9708
200 200 200 200 200 200 200 200 200 200
Averg_ResP -0.187 -0.170 0.348 -0.096 0.423 0.077 0.019 0.057 -0.003 1
0.0081 0.0163 0.0000 0.1768 0.0000 0.2771 0.7937 0.4195 0.9708 0
200 200 200 200 200 200 200 200 200 200
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ANNEXURE J:  COMMENTS OF PARENTS 
 
• Patient 5: Thank you for looking after her so well during the sedation.  It was 
appreciated. 
• Patient 20: Thank you for your patience and warm affection. 
• Patient 43: Sedation is a very comfortable method to treat the kids. 
• Patient 44: Best way of taking kids to the dentist for pulling teeth.  Will recommend 
it to everybody with kids. 
• Patient 59: Happy with sedation.  Less traumatic on the child. 
• Patient 95: I would recommend sedation. 
• Patient 122: Will recommend at any time. 
• Patient 147: Thank you, it was a pleasant experience. 
• Patient 153: I am pro sedation.  It is also less traumatic. 
• Patient 155: Six year old daughter told experience to family with no fear.  Simple, 
short procedure that will be considered for future dental treatment. 
• Patient 162: She did very well this time.  The previous anaesthetic did not go so 
well.  
• Patient 176: My son is an anxious child, but handled the sedation very well because 
he was pre-informed.  Sedation worked very well for him – thank you.  
• Patient 177: His sedation took a lot longer to wear off than his brother’s, therefore 
the possible aggressive behaviour and biting of the tong.  I am grateful for the 
room’s suggestion of the black tea to stop the blood.  I am however grateful to the 
sedation practitioner for the pre-informed details, reactions etc. Apart from the cost 
saving (due to having no medical aid), the sedation choice in rooms instead of 
hospital was by far the better choice.  Thank you.  I am sincerely grateful with your 
professional, friendly service.   
• Patient 179: I understood she would be less conscious.  
• Patient 182: My child had no side-effects.  I am very happy with the sedation.  My 
child handled it very well with no pain.  I would refer anybody to you.   
• Patient 196: The sedation practitioner’s approach to my son was fantastic.  The 
procedure was explained to my son and he was made to feel comfortable.  Thank 
you. 
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ANNEXURE K: Midazolam 
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ANNEXURE L: Propofol 
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ANNEXURE M: Glycopyrrolate 
 
  
 
 
 
 
 111 
ANNEXURE N: Ketamine 
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ANNEXURE O: Sufentanil 
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ANNEXURE P: Mepyramine maleate 
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